https://www.hansabiopharma.com/https://www.hansabiopharma.com/our-company/https://www.hansabiopharma.com/our-company/our-leadership/https://www.hansabiopharma.com/our-company/corporate-governance/https://www.hansabiopharma.com/our-company/corporate-governance/governance-committees/https://www.hansabiopharma.com/our-company/corporate-governance/general-meeting/https://www.hansabiopharma.com/our-company/corporate-governance/remuneration-policy/https://www.hansabiopharma.com/our-company/career/https://www.hansabiopharma.com/our-company/contacts/https://www.hansabiopharma.com/focus-areas/https://www.hansabiopharma.com/focus-areas/autoimmune-diseases/https://www.hansabiopharma.com/focus-areas/gene-therapy/https://www.hansabiopharma.com/focus-areas/transplantation/https://www.hansabiopharma.com/disclaimer/https://www.hansabiopharma.com/our-science/https://www.hansabiopharma.com/our-science/imlifidase/https://www.hansabiopharma.com/our-science/hnsa-5487/https://www.hansabiopharma.com/our-science/pipeline/https://www.hansabiopharma.com/our-science/research/https://www.hansabiopharma.com/our-science/partnering/https://www.hansabiopharma.com/our-science/regulatory-status/https://www.hansabiopharma.com/medicines/idefirix/https://www.hansabiopharma.com/medicines/product-related-enquiries/https://www.hansabiopharma.com/search/https://www.hansabiopharma.com/investors/https://www.hansabiopharma.com/investors/presentations-events/https://www.hansabiopharma.com/investors/presentations-events/2022/william-blair-kol-expert-event-innovations-in-organ-transplant/william-blair-kol-expert-event/https://www.hansabiopharma.com/investors/financial-reports/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-publishes-2024-annual-and-sustainability-reports/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-reports-first-quarter-and-interim-january-march-2025-financial-results/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-reports-third-quarter-and-interim-year-to-date-2025-financial-results/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-publishes-2025-annual-and-sustainability-reports/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-jan-mar-2020-ema-process-on-track-an-opinion-from-the-chmp-is-expected-in-the-second-quarter-2020/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-januaryjune-2019/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-januarymarch-2019/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-july--september-2017/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-jan-june-2021/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-publishes-the-annual-report-for-2018/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-januarymarch-2018/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-april-june-2017/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-publishes-annual-report-2020/https://www.hansabiopharma.com/investors/financial-reports/hansa-medicals-annual-report-of-2010-in-swedish-now-available-at-corporate-website/https://www.hansabiopharma.com/investors/financial-reports/interim-report-january-1--june-30-2009/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-publishes-the-annual-report-for-2016/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-year-end-report-2016/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-july--september-2016/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-ab-publ---year-end-report-2015/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-january--september-2015/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-january--june-2015/https://www.hansabiopharma.com/investors/financial-reports/year-end-report-2013/https://www.hansabiopharma.com/investors/financial-reports/hansa-medicals-annual-report-of-2011-in-swedish-has-been-published/https://www.hansabiopharma.com/investors/financial-reports/year-end-release-2010/https://www.hansabiopharma.com/investors/financial-reports/interim-report-january-1--june-30-2008/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-jan-mar-2021/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-jan-jun-2020/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-year-end-report-2018/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-april--june-2018/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-april--june-2016/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-jan-sep-2020/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-publishes-the-annual-report-for-2014/https://www.hansabiopharma.com/investors/financial-reports/hansa-medicals-annual-report-of-2012-in-swedish-has-been-published/https://www.hansabiopharma.com/investors/financial-reports/year-end-release-2009/https://www.hansabiopharma.com/investors/financial-reports/interim-report-january--march-2017/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-publishes-the-annual-report-for-2015/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-ab-publ---interim-report-january-1---june-30-2013/https://www.hansabiopharma.com/investors/financial-reports/year-end-report-2012/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-ab-publ---interim-report-january-1---june-30-2011/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-januaryseptember-2019/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-january--march-2015/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-jan-sept-2021/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-year-end-report-jan-dec-2020/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-publishes-annual-report-2019/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-year-end-report-2019/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-july--september-2018/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-publishes-the-annual-report-for-2017/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-year-end-report-2017/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-interim-report-january--march-2016/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-year-end-report-2014/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-ab-publ---interim-report-january-1---june-30-2014/https://www.hansabiopharma.com/investors/financial-reports/year-end-release-2007/https://www.hansabiopharma.com/investors/financial-reports/hansa-medicals-annual-report-2009-in-swedish-now-available-online/https://www.hansabiopharma.com/investors/financial-reports/hansa-medicals-annual-report-of-2013-has-been-published-in-swedish/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-ab-publ---interim-report-january-1---june-30-2012/https://www.hansabiopharma.com/investors/financial-reports/annual-report-2008-in-swedish/https://www.hansabiopharma.com/investors/financial-reports/year-end-release-2008/https://www.hansabiopharma.com/investors/financial-reports/year-end-release-2011/https://www.hansabiopharma.com/investors/financial-reports/hansa-medical-ab-publ---interim-report-january-1---june-30-2010/https://www.hansabiopharma.com/investors/financial-reports/annual-report-2007-in-swedish/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-january--march-2022/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-publishes-annual-report-2022/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-january-september-2022/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-year-end-report-2021/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-publishes-annual-report-2021/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-half-year-report-2022/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-januarymarch-2023/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-year-end-report-january-december-2022/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-half-year-report-2023/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-january-september-2023/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-publishes-2023-annual-and-sustainability-reports/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-reports-second-quarter-2024-financial-results-and-business-update/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-year-end-report-january-december-2023/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-interim-report-january-march-2024/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-reports-third-quarter-and-interim-january-september-2024-financial-results/https://www.hansabiopharma.com/investors/financial-reports/hansa-biopharma-reports-fourth-quarter-and-full-year-2024-financial-results/https://www.hansabiopharma.com/investors/calendar/https://www.hansabiopharma.com/investors/share/https://www.hansabiopharma.com/investors/share/shareholders/https://www.hansabiopharma.com/investors/share/share-issues/https://www.hansabiopharma.com/investors/analysts/https://www.hansabiopharma.com/investors/ir-contact/https://www.hansabiopharma.com/investors/annual-sustainability-report-2025/https://www.hansabiopharma.com/media/https://www.hansabiopharma.com/media/press-releases/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-has-won-the-2025-swedenbio-award/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-to-host-year-end-report-2025-conference-call/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-reports-fourth-quarter-and-full-year-2025-financial-results/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-presenting-at-td-cowens-46th-annual-health-care-conference/https://www.hansabiopharma.com/media/press-releases/2026/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-participating-at-leerink-global-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-participating-at-lsx-investival-showcase-usa/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-participating-at-dnb-carnegie-healthcare-conference-2026/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-presenting-at-redeye-theme-event-commercialization-in-life-science/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-announces-a-usd-30-million-convertible-note-financing/https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-publishes-2025-annual-and-sustainability-reports/https://www.hansabiopharma.com/media/press-releases/2025/bulletin-from-the-extraordinary-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-participate-in-h-c-wainwright-27th-annual-global-investment-conference/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-presenting-at-the-pareto-16-annual-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2025/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2025/genethon-to-present-preliminary-efficacy-and-safety-data-from-phase-2-trial-of-imlifidase-as-a-pre-treatment-to-gnt-0003-at-esgct-congress-2025/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-participating-in-optimums-17th-annual-healthcare-investor-conference-and-at-nordic-life-science-days-2025/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-host-q3-2025-interim-results-conference-call/https://www.hansabiopharma.com/media/press-releases/2025/data-from-gnt-018-ides-trial-supports-feasibility-of-imlifidase-as-pretreatment-in-gene-therapy-treatment-for-patients-with-criglernajjar-syndrome-who-are-immune-to-aav/https://www.hansabiopharma.com/media/press-releases/2025/hansa-hosts-call-with-distinguished-transplant-surgeons-insights-on-clinical-practice-and-imlifidase-phase-3-results/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-third-quarter-and-interim-year-to-date-2025-financial-results/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-increase-in-number-of-shares-and-votes-2025-10-31/https://www.hansabiopharma.com/media/press-releases/2025/hansa-at-truist-securities-stifel-and-seb-healthcare-conferences/https://www.hansabiopharma.com/media/press-releases/2025/upcoming-kol-call-today-insights-on-clinical-practice-and-imlifidase-phase-3-results/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-presenting-at-jefferies-global-healthcare-conference-and-dnb-carnegies-16th-annual-nordic-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-announce-changes-to-strengthen-european-and-international-organisation/https://www.hansabiopharma.com/media/press-releases/2025/hansa-provides-update-on-pivotal-phase-3-trial-in-anti-glomerular-basement-membrane-anti-gbm-disease/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-presenting-at-44th-annual-j-p-morgan-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-submits-bla-to-fda-for-imlifidase-in-desensitization-for-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-attend-2025-j-p-morgan-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-host-year-end-report-2024-conference-call/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-fourth-quarter-and-full-year-2024-financial-results/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-attend-td-cowen-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-attend-leerink-partners-global-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-completes-enrolment-in-european-phase-3-20-hmedides-19-post-authorization-efficacy-and-safety-study-in-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-publishes-2024-annual-and-sustainability-reports/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-attend-van-lanschot-kempen-life-sciences-conference/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-host-q1-2025-interim-results-conference-call/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-appoints-new-chief-executive-officer/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-first-quarter-and-interim-january-march-2025-financial-results/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-appoints-maria-tornsen-as-chief-operating-officer-and-president-u-s-/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-data-at-the-2025-pns-annual-meeting-demonstrates-potential-of-imlifidase-in-the-treatment-of-gbs/https://www.hansabiopharma.com/media/press-releases/2025/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-plans-restructuring-to-optimize-resource-allocation-and-improve-operational-efficiency/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-host-science-deep-dive-virtual-investor-event-on-guillain-barre-syndrome-on-june-16-2025/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-attend-bio-international-convention/https://www.hansabiopharma.com/media/press-releases/2025/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-increase-in-number-of-shares-and-votes/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-presents-positive-outcomes-of-five-year-follow-up-study-of-imlifidase-in-kidney-transplantation-at-esot-congress-2025-in-london/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-to-host-q2-2025-interim-results-conference-call/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-announces-key-executive-appointments-to-support-continued-growth/https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-announces-supportive-data-from-treatment-with-imlifidase-prior-to-the-administration-of-gene-therapy-for-duchenne-muscular-dystrophy/https://www.hansabiopharma.com/media/press-releases/2025/notice-to-extraordinary-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-to-participate-in-h-c-wainwright-26th-annual-global-investment-conference/https://www.hansabiopharma.com/media/press-releases/2024/evan-ballantyne-to-join-hansa-biopharma-as-chief-financial-officer/https://www.hansabiopharma.com/media/press-releases/2024/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-provides-update-on-business-and-key-financials-ahead-of-the-jp-morgan-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-publishes-2023-annual-and-sustainability-reports/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-increase-in-number-of-shares-and-votes-20240503/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-year-end-report-january-december-2023/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-expects-strong-first-quarter-2024-sales-performance/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-interim-report-january-march-2024/https://www.hansabiopharma.com/media/press-releases/2024/correction-hansa-biopharma-increase-in-number-of-shares-and-votes-20240503/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-publishes-prospectus-for-admission-to-trading-of-shares-on-nasdaq-stockholm/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-to-host-q3-2024-interim-results-conference-call/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharmas-hnsa-5487-achieved-rapid-and-highly-robust-igg-reduction-by-more-than-95-and-clear-redosing-potential-in-first-in-human-trial/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-reports-third-quarter-and-interim-january--september-2024-financial-results/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-to-attend-truist-securities-biopharma-symposium/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-to-attend-jefferies-london-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2024/genethon-and-hansa-biopharma-announce-initiation-of-a-phase-2-trial-of-imlifidase-as-a-pre-treatment-to-gnt-0003-in-severe-crigler-najjar-syndrome/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-completes-enrolment-in-global-pivotal-phase-3-trial-of-imlifidase-in-anti-glomerular-basement-membrane-disease/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-announces-positive-full-results-from-15-hmedides-09-phase-2-study-and-comparative-analysis-of-imlifidase-in-patients-with-guillain-barre-syndrome/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-announces-departure-of-chief-commercial-officer-matthew-shaulis/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-completes-randomization-in-pivotal-phase-3-us-confides-trial/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-to-present-data-at-2024-american-transplant-congress-annual-meeting/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-reports-second-quarter-2024-financial-results-and-business-update/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-to-host-q2-2024-interim-results-conference-call/https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-increase-in-number-of-shares-and-votes/https://www.hansabiopharma.com/media/press-releases/2024/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-year-end-report-january-december-2022/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-completes-enrollment-in-phase-2-study-of-imlifidase-in-guillain-barre-syndrome-gbs/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-announces-positive-reimbursement-decision-for-idefirix-imlifidase-in-the-czech-republic/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-to-host-conference-call-to-provide-year-end-2022-results-and-a-business-update/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-announces-positive-reimbursement-decision-in-spain-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-publishes-annual-report-2022/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-march-2023-and-a-business-update/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-interim-report-januarymarch-2023/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-announces-planned-departure-of-chief-scientific-officer-christian-kjellman/https://www.hansabiopharma.com/media/press-releases/2023/matthew-shaulis-appointed-chief-commercial-officer-and-us-president-of-hansa-biopharma/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-and-genethon-announce-collaboration-to-develop-imlifidase-as-pre-treatment-to-gene-therapy-in-crigler-najjar-syndrome-patients-with-anti-aav-antibodies/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-announces-positive-reimbursement-decision-for-idefirix-imlifidase-in-belgium-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-ab-recognizes-a-write-up-of-sek-1430-billion-in-intangible-assets-related-to-idefirix-in-the-financial-statements-of-the-parent-company---no-impact-on-the-consolidated-financials/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-to-host-conference-call-to-provide-half-year-results-for-january-june-2023-and-a-business-update/https://www.hansabiopharma.com/media/press-releases/2023/imlifidase-demonstrated-90-patient-survival-and-82-graft-survival-at-five-years-in-extended-pooled-analysis-with-data-from-17-hmedides-14-study/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-announces-planned-departure-of-chief-financial-officer-donato-spota/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-plans-restructuring-to-strengthen-long-term-competitiveness-and-advance-key-deliverables/https://www.hansabiopharma.com/media/press-releases/2023/idefirix-imlifidase-receives-provisional-approval-in-australia-as-desensitization-treatment-in-highly-sensitized-patients-prior-to-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-increase-of-the-number-of-votes/https://www.hansabiopharma.com/media/press-releases/2023/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2023/hansa-announces-first-patient-dosed-with-imlifidase-in-a-global-pivotal-phase-3-trial-in-anti-glomerular-basement-membrane-anti-gbm-disease/https://www.hansabiopharma.com/media/press-releases/2023/dr-hitto-kaufmann-appointed-chief-scientific-officer-of-hansa-biopharma/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-nomination-committee-formed/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-interim-report-january-september-2023/https://www.hansabiopharma.com/media/press-releases/2023/imlifidase-demonstrated-positive-safety-tolerability-and-early-efficacy-outcomes-in-15-hmedides-09-phase-2-trial-in-guillain-barre-syndrome-gbs/https://www.hansabiopharma.com/media/press-releases/2023/imlifidase-met-primary-endpoint-in-16-hmedides-12-phase-2-trial-in-patients-with-amr-following-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2023/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2023/first-patient-treated-with-imlifidase-in-an-investigator-initiated-phase-2-study-in-anca-associated-vasculitis/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-half-year-report-2023/https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-announces-encouraging-high-level-results-for-first-in-human-trial-of-hnsa-5487/https://www.hansabiopharma.com/media/press-releases/2023/update-on-confides-phase-3-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2022/the-scottish-medicines-consortium-smc-recommends-use-of-hansa-biopharmas-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-announces-positive-reimbursement-decision-in-italy-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-patients-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-and-medison-pharma-announce-positive-reimbursement-decision-in-poland-for-idefirix-in-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-increase-of-the-number-of-shares-and-votes/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-interim-report-january-september-2022/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-and-partner-sarepta-therapeutics-plan-to-initiate-a-clinical-study-with-imlifidase-as-a-pre-treatment-to-sareptas-srp-9001-gene-therapy-in-dmd-in-2023/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-announces-positive-topline-data-from-the-imlifidase-phase-2-study-in-antibody-mediated-rejection-amr-episodes-post-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-nomination-committee-formed/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-increase-of-the-number-of-shares-and-votes-2022-12-30/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-achieves-great-place-to-work-certification-for-the-third-consecutive-year/https://www.hansabiopharma.com/media/press-releases/2022/correction-hansa-biopharma-nomination-committee-formed/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-issue-and-repurchase-of-class-c-shares-for-incentive-programs/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-september-2022-and-business-update/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-increase-of-the-number-of-shares-and-votes-2022-10-31/https://www.hansabiopharma.com/media/press-releases/2022/european-society-for-organ-transplantations-esot-guidelines-for-desensitization-treatment-of-highly-sensitized-kidney-transplant-patients-published-in-transplant-international/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-half-year-report-2022/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-announces-70-million-non-dilutive-product-finance-transaction-with-novaquest-to-support-continued-development-of-the-companys-antibody-cleaving-enzyme-technology-platform/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-announces-first-patient-treated-in-the-post-authorization-efficacy-study-paes-of-idefirix-imlifidase-in-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2022/increase-of-the-number-of-votes-in-hansa-biopharma/https://www.hansabiopharma.com/media/press-releases/2022/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-half-year-results-for-january-june-2022-and-business-update/https://www.hansabiopharma.com/media/press-releases/2022/nice-recommends-use-of-hansa-biopharmas-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-notice-to-annual-general-meeting/https://www.hansabiopharma.com/media/press-releases/2022/the-nomination-committee-in-hansa-biopharma-proposes-peter-nicklin-as-new-chair-of-the-board-of-directors-at-the-annual-general-meeting-2022/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-completes-enrollment-in-imlifidase-phase-2-study-in-antibody-mediated-rejection-amr-episodes-post-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-announces-temporary-marketing-authorization-in-switzerland-for-idefirix-imlifidase-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-interim-report-january--march-2022/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-granted-added-benefit-asmr-3-by-french-transparency-commission-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-announces-us-fda-acceptance-of-investigational-new-drug-ind-application-for-phase-3-study-of-imlifidase-in-anti-gbm-disease/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-march-2022-and-business-update/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-publishes-annual-report-2021/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-and-medison-pharma-announce-marketing-authorization-in-israel-for-idefirix-imlifidase-for-desensitization-treatment-of-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-and-german-payer-head-association-agree-on-reimbursement-price-for-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2022/key-data-demonstrating-the-potential-of-hansa-biopharmas-imlifidase-to-significantly-alter-course-of-anti-gbm-disease-published-in-jasn/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-announces-positive-early-access-decision-by-french-haute-autorite-de-sante-to-use-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-year-end-report-2021/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-for-2021-and-business-update/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-provides-business-update-including-certain-key-financials/https://www.hansabiopharma.com/media/press-releases/2022/hansa-biopharma-enters-into-agreement-with-askbio-to-evaluate-feasibility-of-imlifidase-as-pre-treatment-ahead-of-gene-therapy-in-pompe-disease/https://www.hansabiopharma.com/media/press-releases/2021/increase-of-the-number-of-shares-and-votes-in-hansa-biopharma-ab/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-enrolls-first-patient-in-us-randomized-controlled-pivotal-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-issue-and-repurchase-of-class-c-shares-for-incentive-programs/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-and-medison-pharma-announce-multiregional-commercialization-partnership-for-hansas-desensitization-treatment-for-kidney-transplant-in-central-eastern-europe-and-israel/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-to-initiate-phase-3-study-of-imlifidase-to-treat-anti-glomerular-basement-membrane-anti-gbm-disease-after-successful-pre-ind-meeting-with-us-fda/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-nomination-committee-formed/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-announces-it-has-confidentially-submitted-a-draft-registration-statement-on-form-f-1-to-the-us-sec-relating-to-a-potential-us-ipo/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-interim-report-jan-sept-2021/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-september-2021-and-business-update/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-presented-new-data-on-imlifidase-at-the-european-society-for-organ-transplantation-esot-congress/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-announces-participation-in-fall-investor-conferences-and-provides-updated-financial-calendar/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-achieves-great-place-to-work-certification-for-second-consecutive-year/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-announces-reimbursement-in-the-netherlands-of-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-interim-report-jan-june-2021/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-announces-long-term-follow-up-data-demonstrating-3-year-graft-survival-of-84-after-imlifidase-treatment-and-transplantation/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-first-half-2021-and-business-update/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-announces-decision-by-swedish-new-therapies-council-to-recommend-use-of-idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-announces-study-design-for-a-us-randomized-controlled-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients/https://www.hansabiopharma.com/media/press-releases/2021/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-interim-report-jan-mar-2021/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-interim-results-from-q1-2021-and-business-update/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-notice-to-annual-general-meeting/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-publishes-annual-report-2020/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-enters-preclinical-research-collaboration-with-argenx/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-appoints-dr-magnus-korsgren-as-head-of-research--development/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-year-end-report-jan-dec-2020/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-2020-and-business-update/https://www.hansabiopharma.com/media/press-releases/2021/hansa-biopharma-provides-business-update-incl-certain-key-financials-ahead-of-the-jp-morgan-global-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-to-present-at-the-39th-annual-jp-morgan-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-nomination-committee-formed/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-interim-report-jan-sep-2020/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharm-announces-positive-high-level-data-from-investigator-initiated-phase-2-trial-with-imlifidase-to-treat-anti-gbm-disease/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-to-host-capital-markets-day-on-thursday-october-29-2020-in-copenhagen/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-ab-certified-as-a-great-place-to-work-/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-provides-updated-guidance-on-its-clinical-programs/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-announces-participation-in-fall-conferences-and-an-updated-financial-calendar/https://www.hansabiopharma.com/media/press-releases/2020/the-eu-commission-grants-conditional-approval-for-idefirixtm-imlifidase-in-highly-sensitized-kidney-transplant-patients-in-the-european-union/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-announces-increase-in-number-of-shares-and-votes/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-expands-the-leadership-team-with-the-appointment-of-katja-margell-as-new-head-of-corporate-communications/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-interim-report-jan-jun-2020/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-announces-successful-completion-of-sek-11bn-usd-121m-placing-of-newly-issued-shares/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-announces-intention-to-carry-out-a-placing-of-new-ordinary-shares/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-announces-exclusive-agreement-with-sarepta-therapeutics-to-develop-and-promote-imlifidase-as-pre-treatment-ahead-of-gene-therapy-in-select-indications/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-half-of-2020-and-business-update/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-receives-positive-chmp-opinion-for-idefirixtm-imlifidase-for-kidney-transplant-in-eu/https://www.hansabiopharma.com/media/press-releases/2020/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-appoints-achim-kaufhold-as-cmo-to-support-the-expansion-outside-transplantation/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-submits-responses-to-outstanding-questions-from-ema-on-may-26-review-is-on-track-an-opinion-from-chmp-is-expected-by-end-of-june/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-announces-upcoming-presentations-including-a-late-breaking-poster-presentation-at-the-2020-american-transplant-congress/https://www.hansabiopharma.com/media/press-releases/2020/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-to-participate-in-five-upcoming-investor-conferences-during-may-and-june/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-interim-report-jan-mar-2020-ema-process-on-track-an-opinion-from-the-chmp-is-expected-in-the-second-quarter-2020/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-quarter-of-2020-and-business-update/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-publishes-annual-report-2019/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-announces-long-term-follow-up-data-that-demonstrates-2-year-graft-survival-of-89-after-imlifdase-treatment-and-transplantation/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-to-participate-in-two-upcoming-investor-conferences/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-year-end-report-2019/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-completes-enrollment-in-anti-gbm/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-2019-and-business-update/https://www.hansabiopharma.com/media/press-releases/2020/hansa-biopharma-provides-business-update-ahead-of-the-jp-morgan-global-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-has-agreed-with-the-fda-on-a-regulatory-path-forward-for-imlifidase-in-kidney-transplantation-of-highly-sensitized-patients-in-the-us/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-nomination-committee-formed/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-interim-report-januaryseptember-2019/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-the-first-nine-months-of-2019-and-business-update/https://www.hansabiopharma.com/media/press-releases/2019/increase-of-number-of-shares-and-votes-in-hansa-biopharma-ab/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-confirms-follow-up-meeting-with-fda/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-positive-results-presented-at-esot-imlifidase-enabled--transplantation-in-46-sensitized-patients/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-issue-and-re-purchase-of-class-c-shares-for-incentive-programme/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-new-imlifidase-data-presented-at-esot-copenhagen/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-to-participate-in-three-upcoming-investor-conferences/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-interim-report-januaryjune-2019/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-to-host-conference-call-to-provide-second-quarter-2019-business-update/https://www.hansabiopharma.com/media/press-releases/2019/plenary-presentation-at-the-2019-american-transplant-congress-demonstrates-significant-reduction-in-time-on-the-waitlist-for-patients-treated-with-imlifidase-compared-to-matched-controls/https://www.hansabiopharma.com/media/press-releases/2019/bulletin-from-the-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-to-participate-in-ubs-global-healthcare-conference-and-rbc-capital-markets-global-healthcare-conference-in-new-york-city/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-announces-upcoming-presentations-at-the-2019-american-transplant-congress/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-expands-leadership-team-with-dedicated-roles-for-corporate-communications-investor-relations-and-business-development/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-interim-report-januarymarch-2019/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-to-host-conference-call-to-provide-first-quarter-2019-business-update/https://www.hansabiopharma.com/media/press-releases/2019/notice-to-annual-general-meeting-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-receives-ethics-and-regulatory-clearance-to-start-phase-2-study-of-imlifidase-in-guillain-barre-syndrome/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-divests-its-equity-holding-in-genovis/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-publishes-the-annual-report-for-2018/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-receives-ethics-and-regulatory-clearance-to-start-phase-2-study-of-imlifidase-in-acute-antibody-mediated-rejection-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-announces-selection-of-nicer-lead-candidate/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-to-present-at-the-cowen-39th-annual-health-care-conference/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-announces-european-medicines-agency-accepts-marketing-authorization-application-for-idefirix-imlifidase/https://www.hansabiopharma.com/media/press-releases/2019/increase-of-number-of-shares-and-votes-in-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-year-end-report-2018/https://www.hansabiopharma.com/media/press-releases/2019/hansa-biopharma-appoints-donato-spota-as-new-chief-financial-officer/https://www.hansabiopharma.com/media/press-releases/2019/hansa-medical-to-host-conference-call-to-provide-year-end-report-2018-business-update/https://www.hansabiopharma.com/media/press-releases/2019/increase-of-number-of-votes-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2019/hansa-medical-announces-appointment-of-anne-safstrom-lanner-as-vice-president-global-human-resources/https://www.hansabiopharma.com/media/press-releases/2019/hansa-medical-ab-provides-regulatory-update-for-imlifidase-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-ab-to-change-name-to-hansa-biopharma-ab/https://www.hansabiopharma.com/media/press-releases/2018/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-ab-announces-increase-in-number-of-shares-and-votes/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-ab-to-present-at-the-evercore-isi-healthconx-conference/https://www.hansabiopharma.com/media/press-releases/2018/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-interim-report-july--september-2018/https://www.hansabiopharma.com/media/press-releases/2018/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2018/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab/https://www.hansabiopharma.com/media/press-releases/2018/presentation-at-asn-kidney-week-2018-highlights-stable-renal-function-at-up-to-24-months-following-transplantation-enabled-by-imlifidase/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medicals-nomination-committee-for-the-agm-2019-appointed-and-2019-financial-calendar-published/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-to-report-interim-results-for-the-third-quarter-of-2018-and-host-conference-call-and-webcast/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-receives-positive-opinion-for-orphan-drug-designation-in-the-eu-for-imlifidase-for-anti-gbm-disease/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-receives-fda-fast-track-designation-for-imlifidase-for-transplantation/https://www.hansabiopharma.com/media/press-releases/2018/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ-2018-10-05/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-reports-positive-final-top-line-results-from-two-phase-2-studies-of-imlifidase-for-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-announces-appointment-of-vincenza-nigro-as-vice-president-global-medical-affairs/https://www.hansabiopharma.com/media/press-releases/2018/issue-and-repurchase-of-class-c-shares-for-incentive-program/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-initiates-follow-up-study-of-patients-treated-with-lead-candidate-imlifidase-ides-prior-to-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2018/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ-2018-07-31/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-interim-report-april--june-2018/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-to-host-conference-call-to-provide-second-quarter-2018-business-update/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-lead-candidate-imlifidase-ides-granted-orphan-drug-designation-by-the-fda-for-anti-gbm-antibody-disease/https://www.hansabiopharma.com/media/press-releases/2018/increase-of-number-of-shares-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medicals-warrant-program-to2015-has-opened-for-exercise-and-subscription-of-shares/https://www.hansabiopharma.com/media/press-releases/2018/presentation-at-the-2018-american-transplant-congress-highlights-the-long-term-risk-benefit-profile-of-imlifidase-ides-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2018/long-term-follow-up-data-from-investigator-initiated-phase-ii-study-with-imlifidase-ides-to-be-presented-at-2018-american-transplant-congress-atc/https://www.hansabiopharma.com/media/press-releases/2018/bulletin-from-the-annual-general-meeting-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-interim-report-januarymarch-2018/https://www.hansabiopharma.com/media/press-releases/2018/notice-to-annual-general-meeting-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-to-host-conference-call-to-provide-first-quarter-2018-business-update/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-publishes-the-annual-report-for-2017/https://www.hansabiopharma.com/media/press-releases/2018/the-american-journal-of-transplantation-publishes-results-from-hansa-medicals-first-phase-ii-study-with-ides/https://www.hansabiopharma.com/media/press-releases/2018/soren-tulstrup-appointed-new-president-and-ceo-of-hansa-medical/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-receives-fda-orphan-drug-designation-for-ides-and-the-treatment-of-guillain-barre-syndrome/https://www.hansabiopharma.com/media/press-releases/2018/intermediate-evaluation-of-a-sub-population-in-the-highdes-study-demonstrates-good-kidney-function-55-months-median-post-transplantation/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-year-end-report-2017/https://www.hansabiopharma.com/media/press-releases/2018/hansa-medical-to-host-conference-call-to-provide-year-end-report-2017-business-update/https://www.hansabiopharma.com/media/press-releases/2018/increase-of-number-of-votes-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2018/completed-enrollment-in-hansa-medicals-international-multi-center-phase-ii-study-highdes/https://www.hansabiopharma.com/media/press-releases/2018/finalized-enrollment-in-us-phase-ii-study-with-ides-in-highly-sensitized-patients/https://www.hansabiopharma.com/media/press-releases/2017/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2017/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2017/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medicals-nomination-committee-for-the-agm-2018-appointed/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-interim-report-july--september-2017/https://www.hansabiopharma.com/media/press-releases/2017/the-time-point-for-hansa-medicals-third-quarter-2017-business-update-conference-call-has-been-changed/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-announces-sudden-death-of-ceo-goran-arvidson/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-third-quarter-2017-business-update/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medicals-capital-market-days-provide-an-update-on-number-of-patients-included-in-the-companys-kidney-transplantation-and-anti-gbm-studies/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medicals-capital-market-days-provide-an-update-on-number-of-patients-included-in-the-companys-kidney-transplantation-and-anti-gbm-studies-2017-10-03/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-announces-agenda-for-capital-markets-days-in-stockholm--london/https://www.hansabiopharma.com/media/press-releases/2017/save-the-date-tuesday-3--wednesday-4-october-2017-hansa-medicals-capital-markets-days-stockholm--london/https://www.hansabiopharma.com/media/press-releases/2017/the-new-england-journal-of-medicine-publishes-results-from-phase-ii-studies-of-hansa-medicals-lead-candidate-ides-in-highly-sensitized-patients/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-interim-report-april-june-2017/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-second-quarter-2017-business-update/https://www.hansabiopharma.com/media/press-releases/2017/first-patient-treated-in-phase-ii-study-with-ides-in-anti-gbm-antibody-disease/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-to-present-at-jefferies-2017-global-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2017/increase-of-number-of-shares-and-votes-in-hansa-medical-ab-publ-2017-05-31/https://www.hansabiopharma.com/media/press-releases/2017/resolutions-adopted-at-the-annual-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2017/published-preclinical-results-confirm-ides-potential-in-cancer-immunotherapy/https://www.hansabiopharma.com/media/press-releases/2017/ides-selected-for-ema-priority-medicines-prime-scheme/https://www.hansabiopharma.com/media/press-releases/2017/lead-candidate-ides-discussed-in-fda-workshop/https://www.hansabiopharma.com/media/press-releases/2017/issue-and-repurchase-of-class-c-shares-for-incentive-program/https://www.hansabiopharma.com/media/press-releases/2017/interim-report-january--march-2017/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-publishes-the-annual-report-for-2016/https://www.hansabiopharma.com/media/press-releases/2017/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-first-quarter-2017-business-update/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-appoints-sam-agus-as-new-chief-medical-officer/https://www.hansabiopharma.com/media/press-releases/2017/top-line-clinical-results-from-us-study-with-lead-candidate-ides-to-be-presented-at-the-american-transplant-congress/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-to-present-at-the-oppenheimer-27th-annual-healthcare-conference/https://www.hansabiopharma.com/media/press-releases/2017/novel-pre-clinical-in-vivo-data-demonstrate-the-treatment-potential-of-ides-in-guillain-barre-syndrome-gbs/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-year-end-report-2016/https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-to-host-conference-call-to-provide-fourth-quarter-and-full-year-2016-business-update/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-announces-successful-completion-of-a-phase-ii-clinical-trial-of-ides-in-sensitized-kidney-patients/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-discontinues-its-phase-ii-study-in-acquired-thrombotic-thrombocytopenic-purpura-ttp/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medicals-application-for-orphan-drug-designation-for-ides-in-the-eu-receives-positive-opinion/https://www.hansabiopharma.com/media/press-releases/2016/increase-of-number-of-shares-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2016/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-interim-report-july--september-2016/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medicals-nomination-committee-for-the-agm-2017-appointed/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-proposes-a-directed-share-issue/https://www.hansabiopharma.com/media/press-releases/2016/notice-of-extraordinary-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2016/first-patient-treated-with-ides-in-phase-ii-study-in-acquired-thrombotic-thrombocytopenic-purpura-ttp/https://www.hansabiopharma.com/media/press-releases/2016/first-patient-treated-in-hansa-medicals-highdes-study/https://www.hansabiopharma.com/media/press-releases/2016/top-line-results-from-the-swedish-ongoing-phase-ii-study-with-ides-in-sensitized-patients-presented/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-interim-report-april--june-2016/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-acquires-rights-to-cancer-immunotherapy-using-antibody-modulating-enzymes/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-initiates-pivotal-multicenter-study-in-the-us-with-ides-for-treatment-of-refractory-highly-sensitized-kidney-patients/https://www.hansabiopharma.com/media/press-releases/2016/genovis-ab-enters-settlement-and-license-agreement-with-promega-corporation-in-patent-infringement-case/https://www.hansabiopharma.com/media/press-releases/2016/successful-desensitization-with-ides-in-all-recruited-patients-in-ongoing-us-phase-ii-study/https://www.hansabiopharma.com/media/press-releases/2016/initial-results-from-the-ongoing-swedish-phase-ii-study-with-ides-in-sensitized-kidney-transplant-patients-will-be-presented-at-tts-2016/https://www.hansabiopharma.com/media/press-releases/2016/ongoing-us-study-shows-that-ides-allows-for-transplantation-of-highly-sensitized-patients/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-appoints-henk-doude-van-troostwijk-as-vice-president-commercial-operations/https://www.hansabiopharma.com/media/press-releases/2016/resolutions-adopted-at-the-annual-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-interim-report-january--march-2016/https://www.hansabiopharma.com/media/press-releases/2016/patient-recruitment-completed-in-phase-ii-clinical-study-with-ides-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2016/notice-of-annual-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2016/proposed-chairman-ulf-wiinberg-buys-shares-in-hansa-medical/https://www.hansabiopharma.com/media/press-releases/2016/ulf-wiinberg-proposed-as-new-chairman-and-angelica-loskog-new-board-member/https://www.hansabiopharma.com/media/press-releases/2016/fda-clears-hansa-medicals-ind-application-for-ides-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-publishes-the-annual-report-for-2015/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-postpones-annual-general-meeting/https://www.hansabiopharma.com/media/press-releases/2016/study-results-presented-in-new-england-journal-of-medicine-strengthen-hansa-medicals-belief-in-the-potential-of-ides/https://www.hansabiopharma.com/media/press-releases/2016/farstorps-gard-ab-has-divested-hansa-medical-shares/https://www.hansabiopharma.com/media/press-releases/2016/hansa-medical-ab-publ---year-end-report-2015/https://www.hansabiopharma.com/media/press-releases/2015/swedish-and-international-investors-acquire-2-million-shares-in-hansa-medical-ab-from-farstorps-gard-ab/https://www.hansabiopharma.com/media/press-releases/2015/well-attended-capital-markets-day-by-hansa-medical/https://www.hansabiopharma.com/media/press-releases/2015/data-shows-that-one-dose-of-ides-has-favorable-effect-and-completely-removes-hla-antibodies/https://www.hansabiopharma.com/media/press-releases/2015/data-showing-that-ides-can-silence-memory-b-cells-published-in-journal-of-immunology/https://www.hansabiopharma.com/media/press-releases/2015/trading-of-hansa-medicals-share-initiated-on-nasdaq-stockholm-main-market/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-interim-report-january--september-2015/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medicals-nomination-committee-appointed/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-announces-prospectus/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medicals-shares-admitted-to-trading-on-nasdaq-stockholm/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-applies-for-stock-exchange-listing/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-invites-to-a-capital-markets-day-in-stockholm-november-the-13th-2015/https://www.hansabiopharma.com/media/press-releases/2015/data-from-hansa-medicals-first-phase-ii-study-of-ides-in-sensitized-kidney-transplantation-patients-presented-in-oral-session-at-esot-2015/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-receives-fda-orphan-drug-designation-for-ides/https://www.hansabiopharma.com/media/press-releases/2015/results-from-a-clinical-multicenter-trial-with-hbp-assay-published-in-critical-care-medicine/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-interim-report-january--june-2015/https://www.hansabiopharma.com/media/press-releases/2015/first-patient-in-ides-study-at-cedars-sinai-medical-center-in-los-angeles-receives-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2015/positive-ides-phase-i-data-published-in-scientific-journal-plos-one/https://www.hansabiopharma.com/media/press-releases/2015/first-patient-in-ides-phase-ii-study-transplanted/https://www.hansabiopharma.com/media/press-releases/2015/board-members-management-and-employees-acquire-hansa-medical-shares-and-warrants/https://www.hansabiopharma.com/media/press-releases/2015/hans-schikan-elected-as-new-board-member-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2015/resolutions-adopted-at-the-annual-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-ab-establishes-a-us-medical-advisory-board-for-ides-in-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2015/notice-of-annual-general-meeting-of-hansa-medical-hans-schikan-nominated-to-the-board-of-directors/https://www.hansabiopharma.com/media/press-releases/2015/professor-stanley-jordan-a-leading-expert-in-transplant-immunology-initiates-ides-study-in-usa/https://www.hansabiopharma.com/media/press-releases/2015/goran-arvidson-new-president-and-ceo-of-hansa-medical/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-publishes-the-annual-report-for-2014/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-interim-report-january--march-2015/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medicals-sek-246-million-rights-issue-fully-subscribed/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-postpones-the-publishing-of-the-annual-report-for-the-financial-year-of-2014/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-announces-prospectus-2015-03-18/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-postpones-annual-general-meeting/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medicals-cfo-appointed-acting-ceo/https://www.hansabiopharma.com/media/press-releases/2015/change-of-ownership-in-hansa-medical/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-announces-fully-underwritten-sek-246-million-rights-issue/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-appoints-members-of-committees--lars-bjorck-and-hans-wigzell-external-members-of-scientific-committee/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-licensee-axis-shield-diagnostic-limited-enters-agreement-with-hangzhou-joinstar-biomedical-technology-co-ltd/https://www.hansabiopharma.com/media/press-releases/2015/comments-to-ceo-presentation-at-redeye-on-17-february-2015-at-1830/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-ab-has-engaged-carnegie-investment-bank-ab-as-financial-advisor/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-year-end-report-2014/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-ab-applies-for-listing-on-nasdaq-stockholm/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-develops-second-generation-ides-molecules-for-repeat-dosing/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-ab-announces-cooperation-with-cedars-sinai-medical-centers-comprehensive-transplant-center-and-us-transplantation-expert-stanley-jordan/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-nomination-committee-for-the-annual-general-meeting-2015-has-been-established/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-ab-takes-up-a-20-msek-loan-from-principal-shareholder-nexttobe-ab/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-ab-announces-the-formation-of-a-medical-advisory-board-for-ides-in-anti-gbm-disease/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-appoints-goran-arvidson-as-cfo/https://www.hansabiopharma.com/media/press-releases/2015/successful-phase-2-study-of-ides-in-highly-sensitized-dialysis-patients-awaiting-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-financial-reporting-dates/https://www.hansabiopharma.com/media/press-releases/2015/last-patient-included-in-ides-clinical-phase-ii-study/https://www.hansabiopharma.com/media/press-releases/2014/fredrik-lindgren-appointed-new-president-and-ceo-of-hansa-medical/https://www.hansabiopharma.com/media/press-releases/2014/genovis-ab-files-complaint-for-patent-infringement-by-promega-inc/https://www.hansabiopharma.com/media/press-releases/2014/birgit-stattin-norinder-appointed-new-chairman-of-hansa-medicals-board-of-directors/https://www.hansabiopharma.com/media/press-releases/2014/bo-hakansson-has-passed-away/https://www.hansabiopharma.com/media/press-releases/2014/the-hansa-medical-candidate-drug-ides-has-enabled-successful-kidney-transplantation/https://www.hansabiopharma.com/media/press-releases/2014/hansa-medical-ab-publ---interim-report-january-1---june-30-2014/https://www.hansabiopharma.com/media/press-releases/2014/phase-ii-ides-study-initiated-in-uppsala/https://www.hansabiopharma.com/media/press-releases/2014/hansa-medical-to-present-ides-at-the-2014-world-transplant-congress-in-san-francisco-july-27/https://www.hansabiopharma.com/media/press-releases/2014/hansa-medical-to-present-ides-at-the-2014-bio-international-convention-in-san-diego-usa-on-june-26/https://www.hansabiopharma.com/media/press-releases/2014/swedish-medical-products-agency-approves-hansa-medicals-clinical-phase-ii-study-application-with-ides/https://www.hansabiopharma.com/media/press-releases/2014/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2014/hansa-medicals-annual-report-of-2013-has-been-published-in-swedish/https://www.hansabiopharma.com/media/press-releases/2014/hansa-medicals-rights-issue-oversubscribed/https://www.hansabiopharma.com/media/press-releases/2014/hansa-medical-to-present-ides-at-the-world-orphan-drug-congress-usa-april-24-in-washington-dc/https://www.hansabiopharma.com/media/press-releases/2014/hansa-medical-appoints-medical-advisory-board/https://www.hansabiopharma.com/media/press-releases/2014/the-2014-annual-general-meeting-of-hansa-medical-has-been-rescheduled-to-june-3/https://www.hansabiopharma.com/media/press-releases/2014/hansa-medical-publishes-prospectus-regerading-preferential-rights-issue-at-sek-37-million/https://www.hansabiopharma.com/media/press-releases/2014/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2014/hansa-medical-files-application-for-phase-ii-study-with-ides/https://www.hansabiopharma.com/media/press-releases/2014/notice-of-extraordinary-meeting-of-shareholders-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2014/funding-of-the-phase-ii-study-with-ides-secured/https://www.hansabiopharma.com/media/press-releases/2014/year-end-report-2013/https://www.hansabiopharma.com/media/press-releases/2014/succesfully-completed-phase-i-study-with-ides/https://www.hansabiopharma.com/media/press-releases/2013/hansa-medical-receives-sek-34-million-grant-from-vinnova-to-carry-out-phase-ii-study-with-ides/https://www.hansabiopharma.com/media/press-releases/2013/us-department-of-health-and-human-services--reports-critical-need-for-better-prediction-of-severe-sepsis/https://www.hansabiopharma.com/media/press-releases/2013/hansa-medical-and-axis-shield-report-most-promising-results-from-pivotal-clinical-trial-with-hbp-analysis/https://www.hansabiopharma.com/media/press-releases/2013/all-healthy-subjects-have-been-treated-in-hansa-medicals-phase-i-study-with-ides/https://www.hansabiopharma.com/media/press-releases/2013/hansa-medical-strengthens-its-liquidity/https://www.hansabiopharma.com/media/press-releases/2013/hansa-medical-ab-publ---interim-report-january-1---june-30-2013/https://www.hansabiopharma.com/media/press-releases/2013/promising-research-results-with-endos-published-in-pnas/https://www.hansabiopharma.com/media/press-releases/2013/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2013/https://www.hansabiopharma.com/media/press-releases/2013/hansa-medicals-annual-report-of-2012-in-swedish-has-been-published/https://www.hansabiopharma.com/media/press-releases/2013/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2013/hansa-medical-enters-liquidity-provider-agreement-with-erik-penser-bankaktiebolag/https://www.hansabiopharma.com/media/press-releases/2013/the-annual-general-meeting-of-hansa-medical-has-been-rescheduled-to-may-6-2013/https://www.hansabiopharma.com/media/press-releases/2013/hansa-medicals-clinical-phase-i-study-with-ides-has-been-initiated/https://www.hansabiopharma.com/media/press-releases/2013/year-end-report-2012/https://www.hansabiopharma.com/media/press-releases/2013/hansa-medical-receive-approval-from-swedish-medical-products-agency-to-begin-clinical-phase-i-study-with-ides/https://www.hansabiopharma.com/media/press-releases/2012/hansa-medical-development-partner-axis-shield-diagnostics-launches-ce-marked-elisa-assay-for-measurement-of-hbp/https://www.hansabiopharma.com/media/press-releases/2012/hbp-assay-website-launched/https://www.hansabiopharma.com/media/press-releases/2012/hansa-medical-ab-publ---interim-report-january-1---june-30-2012/https://www.hansabiopharma.com/media/press-releases/2012/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2012/https://www.hansabiopharma.com/media/press-releases/2012/hansa-medicals-annual-report-of-2011-in-swedish-has-been-published/https://www.hansabiopharma.com/media/press-releases/2012/hansa-medicals-rights-issue-with-preferential-rights-has-been-completed/https://www.hansabiopharma.com/media/press-releases/2012/hmd-301-for-diagnosis-of-urinary-tract-infection-novel-clinical-results-published/https://www.hansabiopharma.com/media/press-releases/2012/hansa-medical-granted-patents-in-the-united-states-and-europe-for-the-medical-use-of-ides/https://www.hansabiopharma.com/media/press-releases/2012/hansa-medical-has-been-granted-european-patent-for-diagnostic-method-hmd-301/https://www.hansabiopharma.com/media/press-releases/2012/annual-general-meeting-of-hansa-medical-rescheduled-to-may-14-2012/https://www.hansabiopharma.com/media/press-releases/2012/year-end-release-2011/https://www.hansabiopharma.com/media/press-releases/2012/directed-new-share-issue-by-hansa-medical-ab-publ-completed/https://www.hansabiopharma.com/media/press-releases/2012/bulletin-from-the-extraordinary-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2011/notice-of-extraordinary-meeting-of-shareholders-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medical-executes-a-directed-new-share-issue-to-nxt2b-immediately-followed-by-a-guaranteed-preferential-rights-issue--in-total-msek-46-is-raised/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medical-closes-preclinical-research-project-and-focuses-on-clinical-development-of-enzyme-based-treatment-of-rare-diseases/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medical-ab-publ---interim-report-january-1---june-30-2011/https://www.hansabiopharma.com/media/press-releases/2011/bo-hakansson-increases-ownership-in-hansa-medical-ab-publ-through-acquisition-of-more-than-1-million-shares/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medicals-rights-issue-amounting-sek-29-million-has-been-oversubscribed/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medical-arranges-information-meetings-in-malmo-and-stockholm/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medical-publishes-financial-information-from-its-prospectus-regarding-the-new-share-issue/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medicals-prospectus-for-the-new-share-issue-of-msek-29-has-been-published/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medical-establish-agreement-on-subscription-commitment-and-issuing-guarantee/https://www.hansabiopharma.com/media/press-releases/2011/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2011/https://www.hansabiopharma.com/media/press-releases/2011/hmd-301-for-diagnosis-of-bacterial-meningitis-novel-clinical-results-published/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medicals-annual-report-of-2010-in-swedish-now-available-at-corporate-website/https://www.hansabiopharma.com/media/press-releases/2011/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medicals-board-of-directors-recommend-agm-to-issue-new-shares-to-raise-sek-29-million/https://www.hansabiopharma.com/media/press-releases/2011/annual-general-meeting-of-hansa-medical-rescheduled-to-may-12-2011/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medical-terminates-liquidity-provider-agreement/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medical-and-axis-shield-begin-multi-centre-clinical-study-of-hbp-assay-for-diagnosis-of-severe-sepsis/https://www.hansabiopharma.com/media/press-releases/2011/year-end-release-2010/https://www.hansabiopharma.com/media/press-releases/2011/hansa-medicals-development-partner-axis-shield-signs-option-agreement-with-bio-rad-laboratories-for-commercialisation-of-heparin-binding-protein/https://www.hansabiopharma.com/media/press-releases/2010/hansa-medical-ab-receives-milestone-payment-for-achieving-a-strong-alpha-11-patent-portfolio/https://www.hansabiopharma.com/media/press-releases/2010/hansa-medical-ab-enters-license-agreement-with-human-genome-sciences-inc/https://www.hansabiopharma.com/media/press-releases/2010/hansa-medical-ab-publ---interim-report-january-1---june-30-2010/https://www.hansabiopharma.com/media/press-releases/2010/bulletin-from-the-annual-general-meeting-of-hansa-medical-ab-publ-2010/https://www.hansabiopharma.com/media/press-releases/2010/final-outcome-of-hansa-medicals-rights-issue/https://www.hansabiopharma.com/media/press-releases/2010/hansa-medicals-rights-issue-oversubscribed/https://www.hansabiopharma.com/media/press-releases/2010/hansa-medicals-annual-report-2009-in-swedish-now-available-online/https://www.hansabiopharma.com/media/press-releases/2010/hansa-medicals-annual-report-2009-in-swedish-now-available-online-2010-04-15/https://www.hansabiopharma.com/media/press-releases/2010/notice-of-annual-general-meeting-in-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2010/hansa-medical-rights-issue-prospectus-in-swedish-has-been-published/https://www.hansabiopharma.com/media/press-releases/2010/hansa-medical-to-implement-guaranteed-rights-issue-amounting-to-sek-27-million/https://www.hansabiopharma.com/media/press-releases/2010/year-end-release-2009/https://www.hansabiopharma.com/media/press-releases/2009/clinical-research-results-with-hmd-301-published-in-clinical-infectious-diseases/https://www.hansabiopharma.com/media/press-releases/2009/interim-report-january-1--june-30-2009/https://www.hansabiopharma.com/media/press-releases/2009/hansa-medical-and-inverness-medical-innovations-launch-partnership-agreement-for-the-development-of-biopharmaceuticals-to-treat-rheumatoid-arthritis/https://www.hansabiopharma.com/media/press-releases/2009/hansa-medical-and-axis-shield-enter-development-and-license-agreement-regarding-novel-biomarker-for-severe-sepsis/https://www.hansabiopharma.com/media/press-releases/2009/hansa-medical-receives-financing-from-vinnova-for-research-project/https://www.hansabiopharma.com/media/press-releases/2009/press-release-from-the-2009-annual-general-meeting-of-hansa-medical-ab/https://www.hansabiopharma.com/media/press-releases/2009/hansa-medicals-election-committee-moves-for-re-election-of-the-board/https://www.hansabiopharma.com/media/press-releases/2009/annual-report-2008-in-swedish/https://www.hansabiopharma.com/media/press-releases/2009/hansa-medical-divests-research-project/https://www.hansabiopharma.com/media/press-releases/2009/notice-of-the-annual-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2009/year-end-release-2008/https://www.hansabiopharma.com/media/press-releases/2008/hansa-medical-changes-certified-adviser/https://www.hansabiopharma.com/media/press-releases/2008/interim-report-january-1--june-30-2008/https://www.hansabiopharma.com/media/press-releases/2008/hansa-medical-redeems-convertible-loan--positive-earnings-effect-of-sek-151-m/https://www.hansabiopharma.com/media/press-releases/2008/press-release-from-the-annual-general-meeting-of-hansa-medical-ab-publ-on-may-7-2008/https://www.hansabiopharma.com/media/press-releases/2008/annual-report-2007-in-swedish/https://www.hansabiopharma.com/media/press-releases/2008/notice-of-the-annual-general-meeting-of-hansa-medical-ab-publ/https://www.hansabiopharma.com/media/press-releases/2008/year-end-release-2007/https://www.hansabiopharma.com/media/press-releases/2008/hansa-medical-acquires-all-assets-in-cartela-ab/https://www.hansabiopharma.com/media/press-releases/2007/chairman-of-the-board-acquires-shares/https://www.hansabiopharma.com/media/press-releases/2007/hansa-medical-listed-on-first-north/https://www.hansabiopharma.com/media/press-releases/2007/hansa-medical-approved-for-trading-on-first-north/https://www.hansabiopharma.com/media/press-releases/2007/hansa-medicals-new-share-issue-totaling-sek-38-m-fully-subscribed/https://www.hansabiopharma.com/media/media-articles/https://www.hansabiopharma.com/media/media-articles/championing-living-donation-in-the-workplace/https://www.hansabiopharma.com/media/media-articles/who-are-highly-sensitized-patients/https://www.hansabiopharma.com/media/media-articles/time-is-a-key-factor-spotlight-on-guillain-barre-syndrome/https://www.hansabiopharma.com/media/media-articles/individual-needs-of-highly-sensitized/https://www.hansabiopharma.com/media/media-articles/hansa-biopharma-great-place-to-work-2022/https://www.hansabiopharma.com/media/media-articles/acknowledging-disparities-between-sexes-in-kidney-transplantation/https://www.hansabiopharma.com/media/media-articles/building-a-better-knowledge-of-anti-gbm-disease/https://www.hansabiopharma.com/media/media-articles/at-the-intersection-of-patient-centered-care-and-disruptive-science/https://www.hansabiopharma.com/media/media-articles/neutralizing-antibodies/https://www.hansabiopharma.com/media/media-articles/fuelling-the-future-biotech-role/https://www.hansabiopharma.com/media/media-articles/collaboration-advance-treatment/https://www.hansabiopharma.com/media/media-articles/equity-for-highly-sensitized/https://www.hansabiopharma.com/media/media-articles/annas-story/https://www.hansabiopharma.com/media/media-articles/understand-patients-preference-kidney-transplantation/https://www.hansabiopharma.com/media/patients-perspective/https://www.hansabiopharma.com/media/patients-perspective/rons-story/https://www.hansabiopharma.com/media/patients-perspective/kevins-story/https://www.hansabiopharma.com/media/patients-perspective/jonathans-story/https://www.hansabiopharma.com/media/patients-perspective/cris-anns-story-article/https://www.hansabiopharma.com/styleguide/standard-test-page/https://www.hansabiopharma.com/trials-info/nct03943589/https://www.hansabiopharma.com/trials-info/nct03897205/https://www.hansabiopharma.com/trials-info/nct04935177/https://www.hansabiopharma.com/trials-info/nct05679401/https://www.hansabiopharma.com/sv/https://www.hansabiopharma.com/sv/vart-bolag/https://www.hansabiopharma.com/sv/vart-bolag/var-ledning/https://www.hansabiopharma.com/sv/vart-bolag/bolagsstyrning/https://www.hansabiopharma.com/sv/vart-bolag/bolagsstyrning/styrkommitteer/https://www.hansabiopharma.com/sv/vart-bolag/bolagsstyrning/bolagsstamma/https://www.hansabiopharma.com/sv/vart-bolag/bolagsstyrning/ersattningspolicy/https://www.hansabiopharma.com/sv/vart-bolag/karriar/https://www.hansabiopharma.com/sv/vart-bolag/kontakter/https://www.hansabiopharma.com/sv/fokusomraden/https://www.hansabiopharma.com/sv/fokusomraden/autoimmuna-sjukdomstillstand/https://www.hansabiopharma.com/sv/fokusomraden/genterapi/https://www.hansabiopharma.com/sv/fokusomraden/transplantation/https://www.hansabiopharma.com/sv/disclaimer/https://www.hansabiopharma.com/sv/vetenskap/https://www.hansabiopharma.com/sv/vetenskap/imlifidase/https://www.hansabiopharma.com/sv/vetenskap/hnsa-5487/https://www.hansabiopharma.com/sv/vetenskap/pipeline/https://www.hansabiopharma.com/sv/vetenskap/forskning/https://www.hansabiopharma.com/sv/vetenskap/partnerskap/https://www.hansabiopharma.com/sv/vetenskap/regulatorisk-status/https://www.hansabiopharma.com/sv/lakemedel/idefirix/https://www.hansabiopharma.com/sv/lakemedel/rapportera-biverkningar/https://www.hansabiopharma.com/sv/search/https://www.hansabiopharma.com/sv/investerare/https://www.hansabiopharma.com/sv/investerare/presentationer/https://www.hansabiopharma.com/sv/investerare/presentationer/2022/william-blair-kol-expert-event-innovations-in-organ-transplant/william-blair-kol-expert-event/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-publicerar-arsredovisning-och-hallbarhetsredovisning-for-2024/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-redovisar-resultat-for-forsta-kvartalet-och-delarsperioden-januari-mars-2025/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-redovisar-resultat-for-andra-kvartalet-och-delarsperioden-januari-juni-2025/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-redovisar-finansiella-resultat-for-tredje-kvartalet-och-delarsperioden-2025/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-rapporterar-finansiella-resultat-for-fjarde-kvartalet-och-helaret-2025/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-publicerar-arsrapport-och-hallbarhetsredovisning-for-2025/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-delarsrapport-januari-juni-2021/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-delarsrapport-jan-jun-2020/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-offentliggor-arsredovisning-for-2018/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-juli-september-2018/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-april-juni-2017/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-offentliggor-arsredovisning-for-2020/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-bokslutskommunike-2019/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-delarsrapport-januari-september-2021/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-delarsrapport-januarimars-2019/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-offentliggor-arsredovisning-for-2017/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-bokslutskommunike-2017/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-delarsrapport-jan-mar-2020-ema-processen-loper-enligt-plan-ett-utlatande-fran-chmp-vantas-under-andra-kvartalet-2020/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-april-juni-2018/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-juli-september-2017/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/delarsrapport-januari-mars-2017/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-ab-publ--delarsrapport-1-januari--30-juni-2015/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medicals-arsredovisning-for-2013-offentliggjord/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-ab-publ--delarsrapport-1-januari--30-juni-2013/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/bokslutskommunike-2012/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/bokslutskommunike-2011/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medicals-arsredovisning-for-2009-publicerad-pa-bolagets-webbsida/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical--delarsrapport-1-januari-30-juni-2008/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-ab-publ--bokslutskommunike-2015/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medicals-arsredovisning-for-2011-publicerad/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical--bokslutskommunike-2007/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-april-juni-2016/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-januari-mars-2016/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-bokslutskommunike-2018/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-juli-september-2016/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-offentliggor-arsredovisning-for-2016/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-ab-publ--delarsrapport-1-januari--30-juni-2014/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-ab-publ--delarsrapport-1-januari--30-juni-2011/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/delarsrapport-1-januari-30-juni-2009/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/bokslutskommunike-2008/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-januari-september-2015/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/bokslutskommunike-2013/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-delarsrapport-januari-mars-2021/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-delarsrapport-januari-september-2019/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-januari-mars-2015/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-bokslutskommunike-2020/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-delarsrapport-jan-sep-2020/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-offentliggor-arsredovisning-for-2019/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-delarsrapport-januari-juni-2019/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-delarsrapport-januarimars-2018/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-bokslutskommunike-2016/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-offentliggor-arsredovisning-for-2015/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-offentliggor-arsredovisning-for-2014/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-bokslutskommunike-2014/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/bokslutskommunike-2010/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/bokslutskommunike-2009/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/offentliggorande-av-hansa-medicals-arsredovisning-for-2007/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medicals-arsredovisning-for-2012-publicerad/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medicals-arsredovisning-for-2010-publicerad-pa-bolagets-webbsida/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-ab-publ--delarsrapport-1-januari--30-juni-2010/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-ab-publ--arsredovisning-2008/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-medical-ab-publ--delarsrapport-1-januari--30-juni-2012/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-bokslutskommunike-2021/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-delarsrapport-januari--mars-2022/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-halvarsrapport-januari--juni-2022/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-delarsrapport-januariseptember-2022/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-delarsrapport-for-januarimars-2023/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-offentliggor-arsredovisning-for-2021/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-bokslutskommunike-for-januari-december-2022/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-offentliggor-arsredovisning-for-2022/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-bokslutskommunike-for-januaridecember-2023/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-delarsrapport-for-januarimars-2024/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-delarsrapport-januariseptember-2023/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-publicerar-arsredovisning-och-hallbarhetsrapport-for-2023/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-rapporterar-finansiella-resultat-for-andra-kvartalet-2024-och-ger-en-verksamhetsuppdatering/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-halvarsrapport-januarijuni-2023/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharma-rapporterar-finansiella-resultat-for-tredje-kvartalet-2024-och-delarsrapport-for-januariseptember-2024/https://www.hansabiopharma.com/sv/investerare/finansiella-rapporter/hansa-biopharmas-bokslutskommunike-for-januaridecember-2024/https://www.hansabiopharma.com/sv/investerare/kalender/https://www.hansabiopharma.com/sv/investerare/aktieinformation/https://www.hansabiopharma.com/sv/investerare/aktieinformation/aktieagare/https://www.hansabiopharma.com/sv/investerare/aktieinformation/nyemissioner/https://www.hansabiopharma.com/sv/investerare/analytiker/https://www.hansabiopharma.com/sv/investerare/ir-kontakt/https://www.hansabiopharma.com/sv/investerare/arsredovisning-hallbarhetsrapport-2025/https://www.hansabiopharma.com/sv/media/https://www.hansabiopharma.com/sv/media/pressmeddelanden/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-har-vunnit-2025-ars-swedenbio-award/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-bokslutskommunike-for-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-rapporterar-finansiella-resultat-for-fjarde-kvartalet-och-helaret-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharmas-ansokan-for-biologisk-medicinsk-produkt-bla-for-imlifidase-har-accepterats-av-fda/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-presenterar-vid-td-cowens-46th-annual-health-care-conference/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/pdufa-datum-for-hansa-biopharmas-ansokan-om-marknadsgodkannande-for-imlifidase-faststallt-till-19-december-2026/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-deltar-vid-leerink-global-healthcare-conference/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-deltar-vid-lsx-investival-showcase-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-deltar-vid-dnb-carnegie-healthcare-conference-2026/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-presenterar-vid-redeye-theme-event-commercialization-in-life-science/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-offentliggor-finansiering-om-30-miljoner-usd-genom-konvertibla-skuldebrev/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2026/hansa-biopharma-publicerar-arsrapport-och-hallbarhetsredovisning-for-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/kommunike-fran-extra-bolagsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/imlifidase-nar-framgangsrikt-primart-effektmatt-i-den-registreringsgrundande-fas-3-studien-confides-i-usa-for-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-deltar-i-optimums-17e-arliga-healthcare-investor-conference-och-nordic-life-science-days-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-q3-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/data-fran-gnt-018-ides-studien-visar-att-imlifidase-kan-anvandas-som-forbehandling-till-genterapi-for-patienter-med-criegler-najjars-syndrom-och-som-har-antikroppar-mot-aav/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-arrangerar-webcast-med-framstaende-transplantationskirurger-insikter-om-klinisk-praxis-och-fas-3-resultaten-med-imlifidase/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-redovisar-finansiella-resultat-for-tredje-kvartalet-och-delarsperioden-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-okning-av-antalet-aktier-och-roster-2025-10-31/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-deltar-vid-konferenserna-truist-securities-stifel-och-seb-healthcare/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/kommande-kol-samtal-idag-insikter-om-klinisk-praxis-och-fas-3-resultaten-med-imlifidase/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-presenterar-vid-jefferies-global-healthcare-conference-och-dnb-carnegies-16th-annual-nordic-healthcare-conference/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-gor-forandringar-for-att-starka-den-europeiska-och-internationella-organisationen/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-ger-uppdatering-om-den-registreringsgrundande-fas-3-studien-for-anti-glomerular-basalmembransjukdom-anti-gbm/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-presenterar-pa-den-44e-arliga-j-p-morgan-healthcare-konferensen/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-lamnar-in-bla-ansokan-till-fda-for-imlifidase-for-desensitisering-vid-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-bokslutskommunike-for-2024/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharmas-bokslutskommunike-for-januaridecember-2024/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-publicerar-arsredovisning-och-hallbarhetsredovisning-for-2024/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-q1-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-utser-ny-vd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-redovisar-resultat-for-forsta-kvartalet-och-delarsperioden-januari-mars-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-utser-maria-tornsen-till-chief-operating-officer-och-president-u-s-/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/kallelse-till-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-planerar-omstrukturering-for-att-optimera-resursfordelning-och-forbattra-operationell-effektivitet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/kommunike-fran-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-okning-av-antalet-aktier-och-roster/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-q2-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-redovisar-resultat-for-andra-kvartalet-och-delarsperioden-januari-juni-2025/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/hansa-biopharma-tillkannager-bekraftande-resultat-fran-behandling-med-imlifidase-innan-genterapibehandling-for-duchennes-muskeldystrofi/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2025/kallelse-till-extra-bolagsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharmas-bokslutskommunike-for-januaridecember-2023/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-publicerar-arsredovisning-och-hallbarhetsrapport-for-2023/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharmas-delarsrapport-for-januarimars-2024/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-ger-verksamhetsuppdatering-och-finansiell-information-infor-jp-morgan-healthcare-conference/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-okning-av-antalet-aktier-och-roster-20240503/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/evan-ballantyne-tilltrader-som-chief-financial-officer-pa-hansa-biopharma/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-forvantar-sig-stark-forsaljningsutveckling-under-forsta-kvartalet-2024/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-q3-2024/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharmas-hnsa-5487-uppnadde-en-snabb-och-mycket-robust-igg-reduktion-med-mer-an-95-procent-i-den-forsta-kliniska-studien-och-uppvisar-en-tydlig-potential-for-aterdosering/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-rapporterar-finansiella-resultat-for-tredje-kvartalet-2024-och-delarsrapport-for-januariseptember-2024/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/genethon-och-hansa-biopharma-meddelar-att-de-inleder-en-fas-2-studie-med-imlifidase-som-forbehandling-till-gnt-0003-vid-svar-crigler-najjars-syndrom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-slutfor-rekryteringen-till-sin-globala-pivotala-fas-3-studie-med-imlifidase-for-behandling-av-anti-gbm-sjukdom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-meddelar-positiva-fullstandiga-resultat-fran-fas-2-studien-15-hmedides-09-samt-jamforande-analys-av-imlifidase-hos-patienter-med-guillain-barres-syndrom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/kallelse-till-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-publicerar-prospekt-for-upptagande-till-handel-av-aktier-pa-nasdaq-stockholm/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-meddelar-att-foretagets-chief-commercial-officer-matthew-shaulis-planerar-att-lamna-sin-tjanst/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-rapporterar-finansiella-resultat-for-andra-kvartalet-2024-och-ger-en-verksamhetsuppdatering/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-q2-2024/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-presenterar-data-vid-american-transplant-congress-2024/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-slutfor-randomisering-i-den-pivotala-fas-3-studien-confides-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/hansa-biopharma-okning-av-antalet-aktier-och-roster/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2024/kommunike-fran-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-meddelar-att-foretagets-chief-scientific-officer-christian-kjellman-planerar-att-lamna-sin-tjanst/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-bokslutskommunike-for-januari--december-2022/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/matthew-shaulis-utsedd-till-chief-commercial-officer-och-president-for-hansa-biopharma-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharmas-delarsrapport-for-januarimars-2023/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-meddelar-positivt-subvensionsbeslut-for-idefirix-imlifidase-i-tjeckien/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-offentliggor-arsredovisning-for-2022/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-slutfor-rekrytering-till-fas-2-studie-av-imlifidase-for-behandling-av-guillain-barres-syndrom-gbs/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/spanien-subventionerar-hansa-biopharmas-lakemedel-idefirix-imlifidase-for-desensitisering-av-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-januari-mars-2023-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-bokslutskommunike-2022-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-forsta-halvaret-2023-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-okning-av-antalet-roster/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharmas-delarsrapport-januariseptember-2023/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-och-genethon-ingar-samarbete-inom-utveckling-av-imlifidase-som-forbehandling-vid-genterapi-hos-crigler-najjars-syndrom-for-patienter-med-antikroppar-mot-aav/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/kallelse-till-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharmas-lakemedel-idefirix-imlifidase-far-subvention-i-belgien-for-desensitisering-av-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-ab-genomfor-en-uppskrivning-om-1430-miljarder-sek-av-immateriella-tillgangar-hanforligt-till-idefirix-i-moderbolagets-finansiella-rapporter---paverkar-ej-koncernredovisningen/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/idefirix-imlifidas-far-provisoriskt-godkannande-i-australien-for-desensitiseringsbehandling-av-hogsensitiserade-patienter-fore-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-meddelar-lovande-overgripande-resultat-fran-den-forsta-studien-av-hnsa-5487-i-manniska/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/uppdatering-av-confides-fas-3-studie-av-imlifidase-i-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/kommunike-fran-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/forsta-patienten-med-anca-associerad-vaskulit-har-behandlats-med-imlifidase-i-en-provarinitierad-fas-2-studie/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/dr-hitto-kaufmann-utsedd-till-chief-scientific-officer-for-hansa-biopharma/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/imlifidase-visade-90-procent-patientoverlevnad-och-82-procent-graftoverlevnad-efter-fem-ar-i-en-utokad-poolad-analys-med-data-fran-17-hmedides-14-studien-2023-10-17/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharmas-valberedning-utsedd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-planerar-omstrukturering-for-att-starka-den-langsiktiga-konkurrenskraften-och-tidigarelagga-viktiga-leveranser/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/imlifidase-uppnadde-primara-endpoint-i-fas-2-studien-16-hmedides-12-pa-patienter-med-amr-efter-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-meddelar-att-den-forsta-patienten-doserats-med-imlifidase-i-en-global-pivotal-fas-3-studie-av-anti-gbm-sjukdom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharmas-halvarsrapport-januarijuni-2023/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/imlifidase-visade-90-procent-patientoverlevnad-och-82-procent-graftoverlevnad-efter-fem-ar-i-en-utokad-poolad-analys-med-data-fran-17-hmedides-14-studien/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/hansa-biopharma-meddelar-att-foretagets-chief-financial-officer-donato-spota-planerar-att-lamna-sin-tjanst/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2023/imlifidase-uppvisade-positiva-resultat-avseende-sakerhet-tolerabilitet-och-tidig-effekt-i-15-hmedides-09-fas-2-studien-i-guillain-barres-syndrom-gbs/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/scottish-medicines-consortium-smc-rekommenderar-hansa-biopharmas-lakemedel-idefirix-imlifidase-for-desensitiseringsbehandling-av-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-okning-av-antalet-aktier-och-roster/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-tredje-kvartalet-2022-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharmas-delarsrapport-januariseptember-2022/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-okning-av-antalet-roster/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/rattelse-hansa-biopharmas-valberedning-utsedd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-planerar-att-under-2023-tillsammans-med-sin-samarbetspartner-sarepta-therapeutics-inleda-en-klinisk-studie-av-imlifidase-som-forbehandling-till-sareptas-genterapi-srp-9001-mot-dmd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/idefirix-imlifidase-beviljas-nationell-subvention-i-italien-for-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharmas-valberedning-utsedd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-okning-av-antalet-aktier-och-roster-2022-12-30/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-emission-och-aterkop-av-c-aktier-for-incitamentsprogram/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-far-great-place-to-work-certifiering-for-tredje-aret-i-rad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-presenterar-positiva-forsta-data-fran-fas-2-studien-med-imlifidase-for-antikroppsmedierad-avstotning-amr-efter-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-och-medison-pharma-idefirix-beviljas-nationell-subvention-i-polen-for-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/riktlinjer-for-desensitiseringsbehandling-av-hog-sensitiserade-njurtransplantationspatienter-framtagna-av-esot-i-transplant-international/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharmas-halvarsrapport-januari--juni-2022/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-offentliggor-en-produktfinansieringstransaktion-utan-utspadningseffekt-om-70-musd-med-novaquest-transaktionen-stodjer-den-fortsatta-utvecklingen-av-hansas-enzymteknologiplattform/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-meddelar-att-forsta-patienten-behandlats-i-paes-studien-med-idefirix-imlifidase-for-behandling-av-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/okning-av-antalet-roster-i-hansa-biopharma/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/kommunike-fran-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-forsta-halvaret-2022-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/nice-rekommenderar-hansa-biopharmas-lakemedel-idefirix-imlifidase-for-desensitiseringsbehandling-av-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-kallelse-till-arsstamma/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharmas-valberedning-nominerar-peter-nicklin-till-ny-styrelseordforande-infor-arsstamman-2022/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-har-slutfort-rekrytering-till-fas-2-studie-av-imlifidase-som-behandling-av-antikroppsmedierad-avstotning-amr-efter-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-meddelar-tidsbegransat-marknadsgodkannande-i-schweiz-for-idefirix-imlifidase-inom-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharmas-delarsrapport-januari--mars-2022/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-har-tilldelats-klassificering-asmr-3-i-frankrike-for-idefirix-imlifidase-som-desensitiseringsbehandling-for-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-tillkannager-fda-godkannande-av-investigational-new-drug-ind-ansokan-i-usa-for-fas-3-studie-av-imlifidase-vid-anti-gbm-sjukdom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-januari-mars-2022-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-offentliggor-arsredovisning-for-2021/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-och-medison-pharma-tillkannager-godkannande-i-israel-for-idefirix-imlifidase-for-desensitiseringsbehandling-av-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-nar-overenskommelse-om-pris-och-subvention-i-tyskland-for-idefirix-imlifidas-som-desensitiseringsbehandling-for-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/nyckeldata-publicerade-i-jasn-visar-potentialen-hos-hansa-biopharmas-imlifidase-att-avsevart-forandra-sjukdomsforloppet-vid-anti-gbm-sjukdom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/franska-haute-autorite-de-sante-har-fattat-ett-positivt-beslut-att-ge-tidig-tillgang-till-hansa-biopharmas-idefirix-imlifidase-for-desensitiseringsbehandling-av-hogsensitiserade-njurpatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharmas-bokslutskommunike-2021/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-bolagets-bokslutskommunike-for-2021-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-lamnar-verksamhetsuppdatering-inklusive-viss-finansiell-nyckelinformation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2022/hansa-biopharma-ingar-avtal-med-askbio-for-att-utvardera-imlifidas-som-forbehandling-till-genterapi-vid-pompes-sjukdom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/okning-av-antalet-aktier-och-roster-i-hansa-biopharma/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-rekryterar-forsta-patienten-i-usa-till-en-randomiserad-kontrollerad-pivotal-studie-av-imlifidas-hos-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-emission-och-aterkop-av-c-aktier-for-incitamentsprogram/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-och-medison-pharma-ingar-multiregionalt-samarbete-for-kommersialisering-av-hansas-desensitiseringsbehandling-inom-njurtransplantation-i-centrala-osteuropa-och-israel/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-avser-att-initiera-en-fas-3-studie-med-imlifidase-for-behandling-av-anti-gbm-sjukdom-efter-framgangsrikt-radgivningsmote-med-fda-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharmas-valberedning-utsedd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-offentliggor-att-ett-konfidentiellt-utkast-till-registreringsdokument-enligt-form-f-1-har-lamnats-in-till-amerikanska-sec-for-en-potentiell-notering-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-delarsrapport-januari-september-2021/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-januari-september-2021-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-presenterade-nya-data-om-imlifidase-pa-esot-kongressen-european-society-for-organ-transplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-informerar-om-hostens-investerar-konferenser-och-presenterar-en-uppdaterad-finansiell-kalender/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-far-great-place-to-work-certifiering-for-andra-aret-i-rad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharmas-lakemedel-idefirix-imlifidase-for-desensitisering-av-hogsensitiserade-njurtransplantationspatienter-subventioneras-i-nederlanderna/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-delarsrapport-januari-juni-2021/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-offentliggor-langtidsdata-som-visar-en-3-arig-graftoverlevnad-pa-84-procent-efter-behandling-med-imlifidase-och-transplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-forsta-halvaret-2021-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/nt-radet-har-beslutat-att-rekommendera-hansa-biopharmas-behandling-idefirix-imlifidase-som-desensitiseringsbehandling-for-hogsensitiserade-patienter-som-vantar-pa-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-tillkannager-designen-for-en-usa-baserad-randomiserad-kontrollerad-imlifidase-studie-i-hogsensitiserade-njurtransplantationspatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/kommunike-fran-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-delarsrapport-januari-mars-2021/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-forsta-kvartalet-2021-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-kallelse-till-arsstamma/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-offentliggor-arsredovisning-for-2020/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-ingar-prekliniskt-forskningssamarbete-med-argenx/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-utser-dr-magnus-korsgren-till-chef-for-forskning-och-utveckling/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-bokslutskommunike-2020/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-bjuder-in-till-en-webbsand-telefonkonferens-av-bolagets-bokslutskommunike-for-2020-samt-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2021/hansa-biopharma-ger-en-verksamhetsuppdatering-inkl-vissa-finansiella-nyckeltal-infor-jp-morgan-global-healthcare-conference/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-presenterar-bolaget-pa-jp-morgans-39e-arliga-halsovardskonferens/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharmas-valberedning-utsesd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-delarsrapport-jan-sep-2020/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-meddelar-positiva-resultat-fran-den-provarinitierade-fas-2-studien-med-imlifidase-for-behandling-av-anti-gbm-sjukdom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-haller-en-kapitalmarknadsdag-torsdagen-den-29-oktober-2020-i-kopenhamn/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-ab-certifierad-som-ett-great-place-to-work/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-ger-uppdatering-om-kliniska-program/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-meddelar-deltagande-i-hostkonferenser-och-en-uppdaterad-finansiell-kalender/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/eu-kommissionen-beviljar-villkorligt-godkannande-av-idefirixtm-imlifidase-till-hogsensitiserade-patienter-i-eu-som-ska-genomga-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-meddelar-okning-av-antalet-aktier-och-roster/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-utokar-ledningsteamet-med-utnamningen-av-katja-margell-som-ny-head-of-corporate-communications/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-delarsrapport-jan-jun-2020/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-har-framgangsrikt-genomfort-en-riktad-nyemission-av-stamaktier-om-11-miljarder-kronor-121-musd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-avser-att-genomfora-en-riktad-nyemission-av-stamaktier/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-ingar-exklusivt-avtal-med-sarepta-therapeutics-for-utveckling-och-kommersialisering-av-imlifidase-som-forbehandling-infor-genterapi-i-utvalda-indikationer/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-forsta-halvaret-2020-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-erhaller-positivt-chmp-utlatande-for-idefirixtm-imlifidase-for-njurtransplantation-inom-eu/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/kommunike-fran-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-utser-achim-kaufhold-till-cmo-for-att-stodja-expansionen-utanfor-transplantationsomradet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-lamnar-in-svar-pa-utestaende-fragor-fran-ema-den-26-maj-processen-loper-enlig-plan-ett-utlatande-fran-chmp-vantas-i-slutet-av-juni/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-offentliggor-kommande-presentationer-och-en-late-breaking-poster-pa-2020-ars-amerikanska-transplantationskongress-atc/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/kallelse-till-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-kommer-att-delta-i-fem-kommande-investerarkonferenser-under-maj-och-juni/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-delarsrapport-jan-mar-2020-ema-processen-loper-enligt-plan-ett-utlatande-fran-chmp-vantas-under-andra-kvartalet-2020/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-bjuder-in-till-en-telefonkonferens-for-att-presentera-delarsrapporten-for-forsta-kvartalet-2020-och-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-offentliggor-arsredovisning-for-2019/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-offentliggor-langtidsdata-som-visar-en-2-arig-graftoverlevnad-pa-89-procent-efter-behandling-med-imlifidase-och-transplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-kommer-att-delta-pa-tva-kommande-investerarkonferenser/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-bokslutskommunike-2019/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-fullbordar-patientrekryteringen-till-anti-gbm-studien/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-bjuder-in-till-en-webbsand-telefonkonferens-for-att-presentera-bolagets-bokslutskommunike-for-2019-samt-ge-en-uppdatering-av-verksamheten/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2020/hansa-biopharma-presenterar-en-uppdatering-av-verksamheten-infor-jp-morgan-global-healthcare-conference-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-har-natt-en-overenskommelse-med-fda-om-vagen-framat-mot-marknadsgodkannande-for-imlifidase-vid-njurtransplantation-av-hogsensitiserade-patienter-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharmas-valberedning-utsedd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-delarsrapport-januari--september-2019/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-bjuder-in-till-en-webbsand-telefonkonferens-for-att-presentera-bolagets-delarsrapport-for-perioden-januariseptember-2019-samt-ge-en-uppdatering-av-bolagets-verksamhet/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/okning-av-antalet-aktier-och-roster-i-hansa-biopharma/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-bekraftar-uppfoljningsmote-med-fda/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-positiva-resultat-presenterade-pa-esot-imlifidase-mojliggjorde-transplantation-hos-46-sensitiserade-patienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-emission-och-aterkop-av-c-aktier-for-incitamentsprogram/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-nya-imlifidasedata-presenteras-pa-esot-kopenhamn/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-kommer-att-deltaga-pa-tre-kommande-investerarkonferenser/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-delarsrapport-januari--juni-2019/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-delarsrapport-for-andra-kvartalet-2019/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/data-presenterade-pa-2019-american-transplant-congress-visar-signifikant-kortare-vantetid-for-patienter-som-behandlats-med-imlifidase-jamfort-med-matchade-kontroller/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/kommunike-fran-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-presenterar-vid-ubs-global-healthcare-conference-och-rbc-capital-markets-global-healthcare-conference-i-new-york/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-tillkannager-kommande-presentationer-vid-2019-american-transplant-congress/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-forstarker-foretagsledningen-med-nya-befattningar-inom-corporate-communications-investor-relations-och-business-development/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-delarsrapport-januarimars-2019/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-delarsrapport-for-forsta-kvartalet-2019/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/kallelse-till-arsstamma-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-har-fatt-godkant-att-starta-fas-2-studie-med-imlifidase-i-guillain-barres-syndrom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-avyttrar-sitt-aktieinnehav-i-genovis/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-offentliggor-arsredovisning-for-2018/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-har-fatt-godkant-att-starta-fas-2-studie-med-imlifidase-i-akut-antikroppsmedierad-avstotning-i-samband-med-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-tillkannager-val-av-ny-lakemedelskandidat-ur-utvecklingsprogrammet-nicer/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-presenterar-vid-cowen-39th-annual-health-care-conference/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/europeiska-lakemedelsmyndigheten-har-accepterat-hansa-biopharmas-ansokan-om-marknadsgodkannande-for-idefirix-imlifidase/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/okning-av-antalet-aktier-och-roster-i-hansa-biopharma-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-bokslutskommunike-2018/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-utser-donato-spota-till-ny-chief-financial-officer/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-ab-lanserar-nytt-namn-och-ny-logotyp/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-biopharma-ab-launches-new-name-and-unveils-logo/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-medical-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-bokslutskommunike-for-2018/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/okning-av-antalet-roster-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-medical-utser-anne-safstrom-lanner-till-vice-president-global-human-resources/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2019/hansa-medical-ab-ger-uppdatering-gallande-moten-med-regulatoriska-myndigheter-for-imlifidase-vid-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-ab-under-namnbyte-till-hansa-biopharma-ab/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/kommunike-fran-extra-bolagsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/okning-av-antalet-aktier-och-roster-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-presenterar-vid-evercore-isi-healthconx-conference/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/kallelse-till-extra-bolagsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-delarsrapport-juli--september-2018/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/okning-av-antalet-aktier-och-roster-i-hansa-medical-ab-publ-2018-10-31/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/kommunike-fran-extra-bolagsstamma-i-hansa-medical-ab-publ-2018-10-29/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/resultat-presenterade-vid-asn-kidney-week-2018-belyser-fortsatt-stabil-njurfunktion-i-upp-till-24-manader-efter-transplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-tillkannager-valberedning-infor-arsstamman-2019-samt-finansiell-kalender-for-2019/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-publicerar-bolagets-delarsrapport-for-tredje-kvartalet-2018-och-bjuder-in-till-telefonkonferens-och-webbpresentation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-erhaller-positivt-utlatande-gallande-sarlakemedelsstatus-i-eu-for-imlifidase-och-behandling-av-anti-gbm-sjukdom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-erhaller-fast-track-status-for-imlifidase-inom-transplantation-av-fda/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/kallelse-till-extra-bolagsstamma-i-hansa-medical-ab-publ-2018-10-05/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-rapporterar-positiva-finala-resultat-fran-tva-fas-2-studier-med-imlifidase-vid-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-utser-vincenza-nigro-till-vice-president-global-medical-affairs/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/emission-och-aterkop-av-c-aktier-for-incitamentsprogram/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-inleder-en-uppfoljningsstudie-av-patienter-som-behandlats-med-lakemedelskandidaten-imlifidase-ides-infor-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/okning-av-antalet-aktier-och-roster-i-hansamedical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-delarsrapport-april--juni-2018/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-delarsrapport-for-andra-kvartalet-2018/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medicals-lakemedelskandidat-imlifidase-ides-beviljas-sarlakemedelsstatus-orphan-drug-designation-av-fda-for-behandling-av-anti-gbm-sjukdom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/okning-av-antalet-aktier-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/perioden-for-aktieteckning-i-hansa-medicals-teckningsoptionsprogram-to2015-har-inletts/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/presentation-vid-2018-american-transplant-congress-visar-den-langsiktiga-risknytta-profilen-for-imlifidase-ides-vid-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/uppfoljningsresultat-fran-provarinitierad-fas-ii-studie-med-imlifidase-ides-kommer-att-presenteras-vid-2018-american-transplant-congress-atc/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/kommunike-fran-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-delarsrapport-januarimars-2018/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-delarsrapport-for-forsta-kvartalet-2018/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-offentliggor-arsredovisning-for-2017/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/resultaten-fran-hansa-medicals-forsta-fas-ii-studie-med-ides-publiceras-av-american-journal-of-transplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/soren-tulstrup-utsedd-till-ny-vd-och-koncernchef-for-hansa-medical/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-beviljas-sarlakemedelsstatus-for-ides-och-behandling-av-guillain-barres-syndrom-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/preliminar-utvardering-av-en-delpopulation-i-highdes-studien-visar-god-njurfunktion-55-manader-median-efter-transplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-bokslutskommunike-2017/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/hansa-medical-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-bokslutskommunike-for-2017/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/okning-av-antalet-roster-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/fullbordad-patientrekrytering-till-hansa-medicals-internationella-multicenterstudie-highdes/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2018/slutford-rekrytering-av-patienter-till-amerikansk-fas-ii-studie-med-ides-i-hogsensitiserade-patienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/okning-av-antalet-aktier-och-roster-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/kommunike-fran-extra-bolagsstamma-i-hansa-medicalab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/kallelse-till-extra-bolagsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medicals-valberedninginfor-arsstamman-2018-utsedd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-delarsrapport-juli---september-2017/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/tidpunkten-for-hansa-medicals-webbsanda-telefonpresentation-av-bolagets-delarsrapport-for-tredje-kvartalet-2017-andrad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medicals-vd-goran-arvidson-har-hastigt-avlidit/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-delarsrapport-for-tredje-kvartalet-2017/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-uppdaterar-antalet-patienter-som-inkluderats-i-bolagets-kliniska-studier-for-njurtransplantation-och-anti-gbm/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-uppdaterar-antalet-patienter-som-inkluderats-i-bolagets-kliniska-studier-for-njurtransplantation-och-anti-gbm-2017-10-03/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-tillkannager-agenda-infor-kapitalmarknadsdagar-i-stockholm-och-london/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/spara-datumen-3-och-4-oktober-2017hansa-medicals-kapitalmarknadsdagar-i-stockholm-och-london/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/the-new-england-journal-of-medicine-publicerar-resultat-fran-fas-ii-studier-med-ides-i-hogsensitiserade-patienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-delarsrapport-april-juni-2017/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-delarsrapport-for-andra-kvartalet-2017/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/forsta-patienten-behandlad-i-fas-ii-studie-med-ides-i-anti-gbm-sjukdom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-presenterar-vid-jefferies-2017-global-healthcare-conference/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/okning-av-antalet-aktier-och-roster-i-hansa-medical-ab-publ-2017-05-31/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/kommunike-fran-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/publicerade-prekliniska-resultat-bekraftar-ides-potential-inom-cancerimmunterapi/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/ides-har-beviljats-tillgang-till-emas-process-for-prioriterade-lakemedel-prime/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medicals-lakemedelskandidat-ides-diskuterades-i-fda-seminarium/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/emission-och-aterkop-av-c-aktier-for-incitamentsprogram/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/delarsrapport-januari--mars-2017/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-offentliggor-arsredovisning-for-2016/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-delarsrapport-for-forsta-kvartalet-2017/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-utser-sam-agus-till-ny-chief-medical-officer/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/presentation-av-resultat-fran-den-amerikanska-studien-med-ides-vid-american-transplant-congress/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-presenterar-vid-the-oppenheimer-27th-annual-healthcare-conference/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/nya-prekliniska-in-vivo-data-visar-potentialen-for-ides-behandling-i-guillain-barres-syndrom-gbs/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-bokslutskommunike-2016/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2017/hansa-medical-bjuder-in-till-webbsand-telefonpresentation-av-bolagets-bokslutskommunike-for-2016/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-meddelar-framgangsrikt-slutford-fas-ii-studie-med-ides-i-sensitiserade-patienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-avbryter-fas-ii-studie-i-forvarvad-trombotisk-trombocytopen-purpura-ttp/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/europeiska-lakemedelsmyndigheten-ema-lamnar-positivt-utlatande-om-hansa-medicals-ansokan-om-sarlakemedelsstatus-for-ides/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/okning-av-antalet-aktier-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/kommunike-fran-extra-bolagsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-delarsrapport-juli--september-2016/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medicals-valberedning-infor-arsstamman-2017-utsedd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-foreslar-riktad-nyemission/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/kallelse-till-extra-bolagsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/forsta-patienten-behandlad-med-ides-i-fas-ii-studie-i-forvarvad-trombotisk-trombocytopen-purpura-ttp/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/forsta-patienten-behandlad-i-hansa-medicals-studie-highdes/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/resultat-fran-pagaende-svenska-fas-ii-studien-med-ides-i-sensitiserade-patienter-presenterade/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-delarsrapport-april--juni-2016/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-forvarvar-rattigheter-till-immunterapi-baserad-pa-antikroppsmodulerande-enzymer-for-behandling-av-cancer/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-initierar-en-registreringsgrundande-amerikansk-multicenterstudie-med-ides-i-behandlingsresistenta-hogsensitiserade-njurpatienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/genovis-ab-ingar-forliknings--och-licensavtal-med-promega-corporation-i-patenttvist/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/framgangsrik-desensitisering-med-ides-i-samtliga-inkluderade-patienter-i-pagaende-amerikansk-fas-ii-studie/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/inledande-resultat-fran-den-pagaende-svenska-fas-ii-studien-med-ides-i-sensitiserade-transplantationspatienter-presenteras-vid-tts-2016/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/pagaende-amerikansk-studie-visar-att-ides-mojliggor-transplantation-for-hogsensitiserade-patienter/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-utser-henk-doude-van-troostwijk-till-vice-president-commercial-operations/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/kommunike-fran-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-delarsrapport-januari--mars-2016/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/patientrekryteringen-klar-i-den-kliniska-fas-ii-studien-med-ides-i-samband-med-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/foreslagne-styrelseordforanden-ulf-wiinberg-koper-aktier-i-hansa-medical/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/ulf-wiinberg-foreslas-som-ny-styrelseordforande-och-angelica-loskog-som-ny-styrelseledamot/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/fda-ger-hansa-medical-klartecken-att-paborja-kliniska-studier-med-ides-inom-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-offentliggor-arsredovisning-for-2015/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-senarelagger-arsstamma/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/studieresultat-som-presenterats-i-new-england-journal-of-medicine-starker-hansa-medicals-tro-pa-potentialen-hos-ides/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/farstorps-gard-ab-har-genomfort-en-forsaljning-av-aktier-i-hansa-medical/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2016/hansa-medical-ab-publ---bokslutskommunike-2015/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/svenska-och-internationella-investerare-forvarvar-2-miljoner-aktier-i-hansa-medical-fran-farstorps-gard-ab/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/valbesokt-pa-hansa-medicals-kapitalmarknadsdag/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/data-visar-att-en-dos-av-ides-har-gynnsam-effekt-och-helt-tar-bort-hla-antikroppar/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/data-som-visar-att-ides-kan-inaktivera-minnes-b-celler-publicerade-i-journal-of-immunology/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/handel-i-hansa-medicals-aktie-inledd-pa-nasdaq-stockholms-huvudlista/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-delarsrapport-januari--september-2015/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medicals-valberedning-utsedd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-ab-offentliggor-prospekt/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medicals-aktier-har-godkants-for-handel-pa-nasdaq-stockholm/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-ansoker-om-borsnotering/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-bjuder-in-till-en-kapitalmarknadsdag-den-13-november-i-stockholm/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/data-fran-hansa-medicals-forsta-fas-ii-studie-med-ides-i-sensitiserade-patienter-presenterade-pa-esot-2015/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/fortydligande-gallande-beskedet-fran-fda-att-ides-beviljats-sarlakemedelsstatus/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-beviljas-sarlakemedelsstatus-for-ides-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/resultat-fran-klinisk-multicenterstudie-med-hbp-test-publicerade-i-critical-care-medicine/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-ab-publ---delarsrapport-1-januari---30-juni-2015/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/den-forsta-patienten-i-ides-studien-vid-cedars-sinai-medical-center-i-los-angeles-har-njurtransplanterats/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/ides-fas-i-data-publicerade-i-den-vetenskapliga-tidskriften-plos-one/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/forsta-patienten-i-ides-fas-ii-studie-transplanterad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/styrelsemedlemmar-ledning-och-anstallda-forvarvar-aktier-och-teckningsoptioner-i-hansa-medical/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hans-schikan-vald-till-ny-styrelseledamot-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/kommunike-fran-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-ab-bildar-en-medicinsk-radgivande-kommitte-for-ides-inom-njurtransplantation-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/kallelse-till-arsstamma-i-hansa-medical-hans-schikan-nomineras-till-ny-styrelseledamot/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/professor-stanley-jordan-expert-inom-transplantationsimmunologi-paborjar-ides-studie-i-usa/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/goran-arvidson-utnamnd-till-vd-for-hansa-medical/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-offentliggor-arsredovisning-for-2014/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-delarsrapport-januari--mars-2015/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medicals-foretradesemission-pa-246-miljoner-kronor-fulltecknad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-senarelagger-offentliggorandet-av-arsredovisningen-for-rakenskapsaret-2014/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-ab-offentliggor-prospekt-2015-03-18/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-senarelagger-arsstamman/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medicals-cfo-utnamns-till-tillforordnad-vd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/agarforandring-i-hansa-medical/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-ab-offentliggor-fullt-sakerstalld-nyemission-om-246-miljoner-kronor/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-ab-utser-ledamoter-i-utskott--lars-bjorck-och-hans-wigzell-externa-ledamoter-av-vetenskapligt-utskott/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medicals-licenstagare-axis-shield-diagnostic-limited-ingar-avtal-med-hangzhou-joinstar-biomedical-technology-co-ltd/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/kommentarer-till-vd-presentation-pa-redeye-17-februari-2015-kl-1830/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-har-anlitat-carnegie-investment-bank-ab-som-finansiell-radgivare/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-bokslutskommunike-2014/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-ab-ansoker-om-upptagande-till-handel-pa-nasdaq-stockholm/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-utvecklar-andra-generationens-ides-molekyler-for-upprepad-dosering/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-inleder-samarbete-med-cedars-sinai-medical-centers-comprehensive-transplant-center-och-transplantationsspecialist-stanley-jordan/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medicals-valberedning-infor-arsstamman-2015-har-konstituerats/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-upptar-lan-om-20-msek-fran-huvudagaren-nexttobe-ab/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-ab-bildar-en-medicinsk-radgivande-kommitte-for-ides-i-goodpastures-syndrom/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical-utser-goran-arvidson-till-cfo/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/framgangsrik-fas-2-studie-med-ides-i-hogsensitiserade-dialyspatienter-som-invantar-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/hansa-medical---finansiell-kalender-2015/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2015/sista-patient-inkluderad-i-fas-ii-studien-med-ides/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/fredrik-lindgren-utsedd-till-ny-verkstallande-direktor-for-hansa-medical-ab/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/genovis-ab-lamnar-in-stamningsansokan-gallande-patentintrang-av-promega-inc/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/birgit-stattin-norinder-ny-styrelseordforande-i-hansa-medical/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/bo-hakansson-har-avlidit/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medicals-lakemedelskandidat-ides-mojliggjorde-framgangsrik-njurtransplantation/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medical-ab-publ---delarsrapport-1-januari---30-juni-2014/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medicals-fas-ii-studie-med-ides-har-paborjats/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medical-presenterar-ides-vid-2014-ars-world-transplant-congress-i-san-francisco-den-27e-juli/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medical-presenterar-ides-vid-2014-ars-bio-international-convention-i-san-diego-usa-den-26e-juni/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/kommunike-fran-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/lakemedelsverket-godkanner-hansa-medicals-ansokan-om-fas-ii-studie-med-ides/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medicals-arsredovisning-for-2013-offentliggjord/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medicals-nyemission-overtecknad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medical-presenterar-ides-pa-world-orphan-drug-congress-usa-den-24e-april-i-washington-dc/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medical-utser-medicinskt-vetenskapligt-rad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medicals-arsstamma-2014-flyttad-till-den-3-juni/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medical-offentliggor-prospekt-avseende-foretradesemission-om-37-miljoner-kronor/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/kommunike-fran-extra-bolagsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/hansa-medical-ansoker-om-klinisk-fas-ii-studie-for-ides/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/finansiering-av-fas-ii-studie-med-ides-sakrad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/kallelse-till-extra-bolagsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/bokslutskommunike-2013/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2014/framgangsrikt-genomford-fas-i-studie-med-ides/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/hansa-medical-erhaller-34-miljoner-kronor-i-finansiering-fran-vinnova-for-genomforande-av-fas-ii-studie-med-ides/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/rapport-fran-usas-halso--och-socialdepartement-pekar-pa-enormt-behov-av-battre-prediktion-av-sepsis/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/hansa-medical-och-axis-shield-rapporterar-mycket-positiva-resultat-fran-avgorande-klinisk-studie-med-hbp-analys/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/samtliga-friska-forsokspersoner-behandlade-i-hansa-medicals-fas-i-studie-med-ides/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/hansa-medical-forstarker-likviditeten/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/hansa-medical-ab-publ---delarsrapport-1-januari---30-juni-2013/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/lovande-forskningsresultat-med-endos-publicerade-i-pnas/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/kommunike-fran-arsstamma-i-hansa-medical-ab-publ-den-6-maj-2013/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/hansa-medicals-arsredovisning-for-2012-publicerad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/hansa-medical-tecknar-avtal-om-likviditetsgaranti-med-erik-penser-bankaktiebolag/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/nytt-datum-for-hansa-medicals-arsstamma-6-maj-2013/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/hansa-medicals-fas-i-studie-med-ides-har-inletts/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/bokslutskommunike-2012/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2013/hansa-medicals-ansokan-om-genomforande-av-fas-i-studie-av-ides-har-godkants-av-lakemedelsverket/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/hansa-medicals-samarbetspartner-axis-shield-diagnostics-lanserar-ce-markt-elisa-assay-for-kvantifiering-av-hbp/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/hansa-medicals-samarbetspartner-axis-shield-diagnostics-lanserar-hbp-dedikerad-webbplats/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/hansa-medical-ab-publ---delarsrapport-1-januari---30-juni-2012/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/kommunike-fran-arsstamma-i-hansa-medical-ab-publ-den-14-maj-2012/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/hansa-medicals-arsredovisning-for-2011-publicerad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/hansa-medicals-foretradesemission-genomford/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/hmd-301-for-diagnostik-av-urinvagsinfektion-nya-forskningsresultat-publicerade/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/hansa-medical-beviljas-patent-i-usa-och-europa-for-medicinsk-anvandning-av-ides/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/hansa-medical-beviljas-patent-i-europa-for-diagnostikmetoden-hmd-301/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/hansa-medicals-prospekt-avseende-foretradesemission-om-185-miljoner-kronor-publicerat/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/nytt-datum-for-hansa-medicals-arsstamma-14-maj-2012/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/bokslutskommunike-2011/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/riktad-nyemission-i-hansa-medical-ab-publ-genomford/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2012/kommunike-fran-extra-bolagsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/kallelse-till-extra-bolagsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medical-genomfor-riktad-nyemission-till-nxt2b-samt-en-direkt-pafoljande-garanterad-foretradesemission--totalt-tillfors-bolaget-46-msek/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medical-lagger-ner-prekliniskt-forskningsprojekt-och-fokuserar-pa-klinisk-utveckling-av-enzymbaserad-behandling-av-ovanliga-sjukdomar/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medical-ab-publ---delarsrapport-1-januari---30-juni-2011/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/bo-hakansson-utokar-sitt-innehav-i-hansa-medical-ab-publ-genom-forvarv-av-drygt-1-miljon-aktier/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medicals-foretradesemission-om-29-miljoner-kronor-overtecknad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medical-genomfor-informationstraffar-i-malmo-och-stockholm/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medical-offentliggor-finansiell-information-fran-prospekt-avseende-foretradesemission/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medicals-prospekt-avseende-foretradesemission-om-29-miljoner-kronor-publicerat/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medical-ingar-avtal-om-teckningsforbindelse-och-emissionsgaranti/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/kommunike-fran-arsstamma-i-hansa-medical-ab-publ-den-12-maj-2011/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hmd-301-for-diagnostik-av-bakteriell-meningit-nya-kliniska-forskningsresultat-publicerade/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medicals-arsredovisning-for-2010-publicerad-pa-bolagets-webbsida/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medicals-styrelse-foreslar-stamman-att-besluta-om-foretradesemission-om-29-miljoner-kronor/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/nytt-datum-for-hansa-medicals-arsstamma-12-maj-2011/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/avtal-om-likviditetsgaranti-for-aktier-i-hansa-medical-avslutas/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medical-och-axis-shield-startar-klinisk-multicenterstudie-med-hbp-assay-for-diagnos-av-svar-sepsis/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/bokslutskommunike-2010/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2011/hansa-medicals-samarbetspartner-axis-shield-ingar-optionsavtal-med-bio-rad-laboratories-for-kommersialisering-av-heparin-binding-protein/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/hansa-medical-erhaller-milstolpsbetalning-for-etablering-av-en-stark-patentportfolj-kring-alpha-11/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/hansa-medical-ab-ingar-licensavtal-med-human-genome-sciences-inc/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/hansa-medical-ab-publ---delarsrapport-1-januari---30-juni-2010/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/kommunike-fran-arsstamma-2010-i-hansa-medical-ab/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/definitivt-utfall-i-hansa-medicals-foretradesemission/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/hansa-medicals-foretradesemission-overtecknad/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/hansa-medicals-arsredovisning-for-2009-publicerad-pa-bolagets-webbsida/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/hansa-medicals-arsredovisning-for-2009-publicerad-pa-bolagets-webbsida-2010-04-15/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/prospekt-avseende-hansa-medicals-nyemission-publicerat/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/hansa-medical-genomfor-garanterad-foretradesemission-om-27-miljoner-kronor/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2010/bokslutskommunike-2009/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/kliniska-forskningsresultat-med-hansa-medicals-diagnostikmetod-hmd-301-publicerade-i-clinical-infectious-diseases/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/delarsrapport-1-januari--30-juni-2009/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/hansa-medical-och-inverness-medical-innovations-inleder-partnerskapsavtal-for-utveckling-av-biologiska-lakemedel-mot-reumatoid-artrit/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/hansa-medical-och-axis-shield-ingar-utvecklings--och-licensavtal-kring-ny-biomarkor-for-diagnos-av-svar-sepsis/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/hansa-medical-erhaller-vinnova-finansiering-till-forskningsprojekt/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/kommunike-fran-arsstamma-2009-i-hansa-medical-ab/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/hansa-medicals-valberedning-foreslar-omval-av-styrelse/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/hansa-medical-ab-publ---arsredovisning-2008/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/hansa-medical-avyttrar-forskningsprojekt/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2009/bokslutskommunike-2008/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2008/hansa-medical-byter-certified-adviser/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2008/hansa-medical---delarsrapport-1-januari--30-juni-2008/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2008/hansa-medical-loser-konvertibellan--positiv-resultateffekt-om-151-msek/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2008/kommunike-fran-arsstamma-i-hansa-medical-ab-publ-den-7-maj-2008/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2008/offentliggorande-av-hansa-medicals-arsredovisning-for-2007/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2008/kallelse-till-arsstamma-i-hansa-medical-ab-publ/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2008/hansa-medical---bokslutskommunike-2007/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2008/hansa-medical-forvarvar-samtliga-tillgangar-i-cartela-ab/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2007/styrelseordforande-forvarvar-aktier/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2007/hansa-medical-klart-for-handel-pa-first-north/https://www.hansabiopharma.com/sv/media/pressmeddelanden/2007/hansa-medicals-nyemission-om-38-msek-fulltecknad/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/framja-levande-donation-pa-arbetsplatsen/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/vilka-ar-hogsensitiserade-njurpatienter/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/tid-ar-en-viktig-faktor-guillain-barres-syndrom/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/individuella-behoven-hogsensitiserade-patienter/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/hansa-gptw2022/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/skillnader-mellan-konen-vid-njurtransplantationer-i-stralkastarljuset-pa-varldsnjurdagen/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/bygga-upp-en-battre-kunskap-om-anti-gbm-sjukdom/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/i-skarningspunkten-mellan-patientcentrerad-vard-och-banbrytande-vetenskap/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/neutraliserande-antikroppar-nabs/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/bioteknikens-roll-att-framja-innovativ-vetenskap/https://www.hansabiopharma.com/sv/media/artiklar-och-insikter/annas-story-sv/https://www.hansabiopharma.com/sv/media/patientperspektivet/https://www.hansabiopharma.com/sv/media/patientperspektivet/rons-story-sv/https://www.hansabiopharma.com/sv/media/patientperspektivet/kevins-story-sv/https://www.hansabiopharma.com/sv/media/patientperspektivet/jonathans-story-sv/